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ABSTRACT

A compound is provided which comprises at least a portion
of an amino acid linker-domain from squalene synthase. In
alternative forms, the compound can include the amino-acid
linker-domain from various fungus, including S. cerevisiae
or the compound can be the functional equivalent and/or
mimics an amino acid linker-domain from squalene syn
thase. A pharmaceutical composition includes the compound
and may further include a pharmaceutical carrier. A method
is provided for treating or controlling cholesterol metabo
lism and ergosterol metabolism in non-fungal organisms.
One method includes a therapeutic treatment in humans by
administering a therapeutically effective amount ofthe com
pound or pharmaceutical composition, to a patient in need of
treatment, therefrom.
3 Claims, 7 Drawing Sheets
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COMPOUNDS AND METHOD OF USE AS
ANTI-INFECTION COMPOUNDS AND
THERAPEUTIC AGENTS TO REGULATE
CHOLESTEROL METABOLISM
CROSS-REFERENCE TO RELATED
APPLICATION
This application claims the benefit of U.S. Provisional
Patent Application No. 61/814,067, filed Apr. 19, 2013, lO
herein incorporated by reference.
FIELD OF THE INVENTION
The presently disclosed subject matter relates to novel
compounds and methods and systems for unique infection
control reagents and new therapeutics. In one example, the
presently disclosed subject matter related to novel com
pounds and methods and systems for unique ergosterol
control reagents, new therapeutics to regulate stern! metabo!ism in humans and plants, and herbicide compositions. The
novel compounds include a functional domain from
squalene synthases, e.g. from S. cerevisiae, such as a 26
amino acid linker-domain. Alternatively, the compounds can
include a portion that mimic the 26 amino acid linker
domain. These compounds can be formulated into anti
fungal compounds. The present invention also relates to
therapeutic agents for controlling cholesterol metabolism
and ergosterol metabolism in non-fungal organisms based
on the aforementioned and other novel compounds which
include a peptide sequence from a linker domain of squalene
synthase (e.g. the 26 amino acid) linker-domain from S.
cerevisiae or sequences which mimics the domain. Some of
the therapeutic agents may be herbicides.
BACKGROUND OF THE INVENTION
The first squalene synthase (SS) gene to be functionally
characterized was isolated from Saccharomyces cerevisiae
and cloned concurrently by the Karst and Robinson groups
(1,2). Both groups utilized the strategy of screening S.
cerevisiae genomic library clones for their ability to func
tionally complement a squalene synthase (erg9)-deficient
yeast line. Interestingly, Jennings, et al. (2) found that a
genomic clone containing only a partial SS gene fragment
was able to restore ergosterol prototrophy even though it
only restored 5% of the normal level of SS enzyme activity.
This finding suggested that low levels of SS enzyme activity
were sufficient to complement the erg9 deficiency in yeast.
Soon afterwards, Robinson, et al. (3) attempted to clone the
SS gene from Homo sapiens and S. pombe using the same
strategy, but isolated only the S. pombe gene by screening
for complementation of the er9-deficient line (3). Having
two SS genes from two species of fungi, these investigators
were able to identify conserved regions within the deduced
protein sequences to which they designed degenerate prim
ers and cloned the human SS homolog using PCR (3).
Robinson, et al. (3) confirmed that the human squalene
synthase gene was unable to restore ergosterol prototrophy
to the erg9-deficient yeast line, but a chimera SS gene
constructed by combining a 5' region of the human gene
containing the putative catalytic domain with a 3' region of
the S. cerevisiae gene containing a membrane-anchoring
domain was able to complement the erg9 deficiency. Rob
inson, et al. (3) suggested that the inability of human SS to
functionally complement the erg9-deficient yeast line was
due to problems with expression or stability of the human
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protein in S. cerevisiae. A few years later, Soltis, et al. (4)
isolated a similar allele of the human squalene synthase gene
by screening a human cDNA library with a rat squalene
synthase gene probe. These investigators also determined
that the human squalene synthase gene was not able to
complement an erg9 deficiency in yeast. They were, how
ever, able to document expression of the human squalene
synthase gene in yeast by recording the corresponding
protein by immuno-blotting methodology, as well as measuring inducible enhancement of SS enzyme activity. This
result conflicted with the notion that a heterologously
expressed SS was not able to complement the erg9 defi
ciency in yeast because of problems with transgene expression or protein stability in yeast, and Soltis, et al. (4)
hypothesized that structural differences in the carboxy
termini of the yeast and human SS may affect localization or
folding of the proteins in association with intracellular
membranes.
The first plant SS was cloned from Arabidopsis (5) and
soon after from Nicotiana benthamiana (6). Nakashima, et
al. (5) failed to isolate anArabidopsis SS gene by screening
for complementation of an erg9 deficient yeast line, and
instead screened plaques of an Arabidopsis cDNA library
with a mouse squalene synthase cDNA probe. Hanley, et al.
(6) used a degenerate primer/PCR approach to isolate a N.
benthamiana SS, and likewise noted that the tobacco SS
gene was unable to restore growth when expressed in an
erg9 deficient yeast strain. Later, Kribii et al. (7) reported
that the Arabidopsis genome contained two highly homolo
gous SS genes organized in a tandem array. This group
confirmed that the Arabidopsis SS could not complement the
erg9 (SS gene) disruption in yeast, but they measured
significant SS enzyme activity in the microsomal fraction of
these yeast. These investigators went on to show that a
chimeric Arabidopsis SS gene containing a substitution
corresponding to the 66 carboxy-terminal amino acids of
Arabidopsis SS with 111 carboxy-terminal amino acids of
the S. pombe SS were sufficient to restore prototrophic
growth of the erg9 knockout in yeast without exogenous
stern!. Radiolabeling studies were also performed with [3H]
FPP fed to microsomes isolated from yeast expressing either
the full length Arabidopsis SS or the Arabidopsis-S. pombe
chimera SS genes, or from wild type yeast. Radiolabel was
incorporated by either the wild type yeast microsomes or
microsomes from the erg9-deficient yeast over-expressing
the Arabidopsis-S. pombe chimera SS into squalene,
squalene-2,3-epoxide, and lanosterol. However, when [3H]
FPP was incubated with microsomes from erg9 deficient
yeast expressing the full length Arabidopsis SS, only radio
labeled squalene was detected. No SS enzyme activity was
detectable in the cytosolic (soluble) fractions of these yeast
lines. These results strongly suggested that active SS was
being expressed and targeted to membrane in all the constructs tested; however, the carboxy-terminal 111 amino
acids of S. pombe were necessary for channeling of squalene
into the ergosterol biosynthetic pathway (7).
In 2000, another fungal squalene synthase was isolated
from Yarrowia li polytica using a degenerate primer
approach (8). The Y. lipolytica SS was found to complement
an erg9 deficient yeast line, albeit the complemented yeast
grew slower than the yeast complemented with the S.
cerevisiae SS gene. Altogether, this result and those of the
other investigators demonstrated that at least three different
fungal SS could complement the erg9 knockout in S. cer
evisiae, but no other SS isolated from animal or plant could
accomplish this task.
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In 2008, Busquets, et al. (9) reported that of the two
created by reciprocal swapping of the DNA sequences
coding for the 91 carboxy-terminal amino acids ofYSS with
annotated SS genomic sequences in Arabidopsis, only one
the corresponding DNA segments ofthe algal (BSS, Botryocoded for a functional SS enzyme. Busquets, et al. also
coccus squalene synthase) and plant (ASS and TSS, Arabi
performed some fluorescence microscopy experiments to
determine the intracellular location of Arabidopsis SS (9). 5 dopsis and tobacco squalene synthase) genes. An additional
24 amino acid truncation of the Y SS carboxy domain is
GFP was tagged to the N-terminus of a full length SS, a SS
indicated by a lack ofcolor in the linear enzyme model. Each
lacking the equivalent of the carboxy-terminal 67 amino
construct is annotated with the specific amino acids labeled
acids, or the GFP was fused directly to a gene fragment
above each depiction. Constructs were independently trans
corresponding to that encoding for the carboxy-terminal 67
amino acids of the SS. All three constructs were transiently 10 formed into a yeast erg9 knockout line, and three indepen
dent transformants for each construct were randomly
co-expressed in onion epidermal cells with an ER-targeted
selected for growth in Yeast Synthetic Drop-out media
version of DsRed. Both the GFP linked to the full length SS
containing 5 mg/I ergosterol. After three days, each culture
and the carboxy-terminal 67 amino acids of SS co-localized
was serially diluted with water to OD600=1, 0.2, 0.04, and
with DsRed, which indicated that these two SS enzymes
were localized to the ER membrane. The GFP-SS fusion 15 0.008, and 5 µI of each dilution spotted on Yeast Synthetic
Drop-out media plates lacking ergosterol. Plates were inculacking the carboxy-terminal 67 amino acids appeared local
bated at 28 ° C. for 72 h. Liquid cultures ofeach transformant
ized to only the cytosol. These authors concluded that the
in TN-7 line were grown in 10 mL of Yeast Synthetic
membrane-sparming region at the carboxy-terminus of SS
Drop-out media containing 5 mg/L ergosterol at room temwas critical for correct targeting of SS to the ER membrane
20 perature for seven days. Organic extracts were prepared and
(9).
analyzed by GC-MS for their squalene content. To validate
These results and the present inventors' observations that
each gene construct, the squalene synthase enzyme activity
the algal Botryococcus braunii SS also could not comple
encoded by each gene was assessed when the gene was
ment the erg9 mutant in yeast suggested that it was not
expressed in Cali-7 yeast. Briefly, 2000xg supematants were
simply targeting of squalene synthase enzyme activity to the
ER membrane of yeast that was important. Some additional 25 prepared and used in enzyme assays containing 3H-FPP and
radiolabeled products separated by TLC and analyzed.
protein domain within the carboxy-terminal region of the
Enzyme activity (pmoles/h/µg total protein) is recorded as a
yeast squalene synthase was necessary to facilitate the
percent of squalene synthase activity measured when the
complementation phenotype.
Y SS gene was expressed in the yeast line. (n=3).
BRIEF DESCRIPTION OF THE DRAWINGS
30
FIG. 3 shows the amino acid alignment of the B. braunii
(AF205791), C. reinhardtii (XM_001703395), A. thaliana
FIG. 1 illustrates various full length and carboxy-termi
(NM_119630), N. benthamiana (U46000.1), H. sapien
nally truncated squalene synthase genes expressed in yeast
(NM_004462), and R. norvegicus (NM_019238) squalene
line CALI7-1 to test for their ability to complement an erg9
synthases relative to those for S. cerevisiae (X59959), S.
deletion. Terminal truncations are indicated by a lack ofgray 35 pombe (NM_001021271), and Y. lipolytica (AF092497)
(Bottom Portion, B) as SEQ ID NOS: 13-24. The alignment
shading in the linear boxed enzyme model with the specific
is limited to the sequences corresponding to the 67 amino
amino acid coordinates labeled above each. The squalene
acid domain of the S. cerevisiae squalene synthase that are
synthases tested are those of S. cerevisiae (Y SS), B. braunii
necessary and sufficient to restore ergosterol prototrophy to
(BSS), R. norvegicus (RSS), N. benthamiana (TSS), and A.
thaliana (ASS). For the erg9 complementation tests, three 40 erg9 deficient yeast. The region boxed and identified as the
truncated/conserved/linker-domain region corresponds to a
independent CALI7-1 transformants of each construct were
stretch of26 amino acids (SEQ ID NOS.: 1-12, respectively)
randomly selected and grown in 2 mL Yeast Synthetic
that appear more conserved than other regions, and particu
Drop-out media (Sigma) containing 5 mg/L ergosterol at 28°
C. for three days, after which the culture was serially diluted
larly well conserved amongst the fungal squalene synthase's
with water to optical densities (600 nm) equal to 1, 0.2, 0.04, 45 (Top portion, A) of SEQ ID NOS: 13-24, respectively.
and 0.008, and 5 µL of each dilution spotted onto Yeast
FIG. 4 shows functional assessment ofthe role a 26 amino
Synthetic Drop-out media plates without any exogenous
acid peptide sequence within fungal squalene synthases
ergosterol. Plates were incubated at 28 ° C. for 72 hours.
plays in facilitating the complementation ofthe erg9 mutant.
Liquid cultures ofeach construct were also transformed into
Reciprocal constructs were created by swapping the indi
TN-7 (CALI7-1 containing an additional mutation to knock- 50 cated 26 amino acids of the yeast squalene synthase (YSS)
out the squalene epoxidase gene, hence the genotype of
for the corresponding amino acids of an algal squalene
TN-7 is erg9, ergl) were grown in 10 mL ofYeast Synthetic
synthase (BSS) and a higher plant squalene synthase (ASS).
Drop-out media containing 5 mg/L ergosterol at room tem
Three independent Cali-7 transformants for each construct
perature for seven days. Organic extracts were prepared and
were randomly selected, grown in Yeast Synthetic Drop-out
analyzed by GC-MS for their squalene content. To validate 55 media (Sigma) containing 5 mg/I ergosterol for three days,
each gene construct, the squalene synthase enzyme activity
after which serial dilutions were prepared corresponding to
encoded by each gene was assessed when the gene was
optical densities at 600 nm equivalent to 1, 0.2, 0.04, and
expressed in Cali7-1 yeast. Briefly, 2,000xg supematants
0.008, and 5 µI of each dilution spotted onto Yeast Synthetic
were prepared and used in enzyme assays containing
Drop-out media plates lacking ergosterol. Plates were incu
3H-FPP and radiolabeled products separated by TLC and 60 bated at 28 ° C. for 72 h. Liquid cultures ofeach transformant
analyzed. Enzyme activity (pmoles/h/µg total protein) is
in TN-7 line were grown in 10 mL of Yeast Synthetic
recorded as a percent ofsqualene synthase activity measured
Drop-out media containing 5 mg/L ergosterol at room tem
when the Y SS gene was expressed in the yeast line. (n=3).
perature for seven days. Organic extracts were prepared and
FIG. 2 shows the carboxy-terminal amino acids of Y SS
analyzed by GC-MS for their squalene content. To validate
are necessary and sufficient when appended to heterologous 65 each gene construct, the squalene synthase enzyme activity
squalene synthase genes to confer ergosterol prototrophic
encoded by each gene was assessed when the gene was
growth to an erg9 knockout yeast line. Constructs were
expressed Cali-7 yeast. Briefly, 2000xg supematants were
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prepared and used in enzyme assays containing 3H-FPP and
radiolabeled products separated by TLC and analyzed.
Enzyme activity (pmoles/h/µg total protein) is recorded as a
percent of squalene synthase activity measured when the
YSS gene was expressed in the yeast line. n=3
FIG. 5 shows evaluating the contribution of a carboxy
terminal sequence of 26 amino acids conserved amongst
fungi to the complementation and restoration of ergosterol
prototrophy to an erg9 knockout yeast line. Full-length S.
cerevisiae and Arabidopsis squalene synthase genes were
constructed in which the indicated amino acids correspond
ing to residues 353 to 378 ofYSS and residues 345 to 370
ofASS were exchanged with one another in either the YSS
gene (mutants a-e) or the ASS gene (mutants f-j) (in lighter
gray, ASS amino acids substituted into the YSS gene; in
darker gray, YSS residues substituted into the ASS gene).
Each construct was independently transformed into the
Cali7-1 erg9 mutant line, 3 independent transformants were
randomly selected and grown in Yeast Synthetic Drop-out
media (Sigma) containing 5 mg/I ergosterol for 3 days.
Aliquots of each culture were then diluted with water to
optical densities (600 nm) corresponding to 1, 0.2, 0.04, and
0.008, and 5 µI of each dilution spotted on Yeast Synthetic
Drop-out media plates lacking ergosterol. Plates were incubated at 28 ° C. for 72 h. Liquid cultures ofeach transformant
in TN-7 line were grown in 10 mL of Yeast Synthetic
Drop-out media containing 5 mg/L ergosterol at room tem
perature for seven days. Organic extracts were prepared and
analyzed by GC-MS for their squalene content. To validate
each gene construct, the squalene synthase enzyme activity
encoded by each gene was assessed when the gene was
expressed Cali-7 yeast. Briefly, 2000xg supematants were
prepared and used in enzyme assays containing 3H-FPP and
radiolabeled products separated by TLC and analyzed.
Enzyme activity (pmoles/h/µg total protein) is recorded as a
percent of squalene synthase activity measured when the
YSS gene was expressed in the yeast line. n=3.
FIG. 6 shows confocal microscopy images ofCali-7 yeast
expressing various fluorescent tagged squalene synthase
enzymes. Constructs were created by fusing efGFP or
DsRedl in frame and connected by a (GSGG)2 linker to the
amino terminus ofYSS, BSS-YSS-BSS (BYB), and YSStr,
or BSS, respectively. These constructs were cloned into
standard yeast expression vectors, Yep352-Ura or pESCLeu. Various combinations of fluorescent-tagged squalene
synthases or a CFP-tagged ER marker (12) were trans
formed into Cali-7 yeast and positive transformants were
grown in Yeast-synthetic Drop-out media containing 5 mg/L
ergosterol for three days. Confocal laser scanning micrographs were acquired on an Olympus FVl 000 microscope
(Olympus America Inc., Melville, N.Y.).
FIG. 7 shows the 26 amino acid stretch ofYSS can inhibit
the growth of yeast. Constructs were created in which the
C-terminal 92 AA ofYSS, the C-terminal 64 AA ofYSS, the
C-terminal 66 AA ofASS, the C-terminal 92 AA ofYSS in
which the 26 AA domain is replaced by the corresponding of
ASS or BSS, and the C-terminus of either ASS or BSS in
which the 26 AA domain is replaced by the corresponding of
YSS were cloned into the pESC-Ura (Gall and GallO
promoters) vector. Constructs were transformed into
BY4741 yeast and positive transformants were grown in 2
mL of Yeast-Synthetic Drop-out medium for 4 days. Serial
dilutions (Corresponding to O.D.600=0.5, 0.1, 0.02, and
0.004) were plated on selection media containing either
glucose or galactose as the carbon source. Pictures were
taken after 4 days growth at 28 ° C.

FIG. 8 shows a phylogenetic tree for the amino acid
sequence ali griment of the 26 amino acid linker domain of
squalene synthases from diverse organisms. The clustering
of the sequences for plants (Plantae), animals (Animalia)
and fungi (Fungi) are indicative of the uniqueness of these
domains to the respective organisms in each kingdom and
the distinct functional significance of this domain for each
kingdom as illustrated in FIGS. 4 and 7 above.
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SUMMARY OF THE INVENTION
The present invention relates to a compound consisting
essentially of at least a portion of an amino acid linker
domain for squalene synthase, e.g. squalene synthase from
S. cerevisiae. In one specific form, the compound includes a
26 amino acid linker-domain, e.g. an amino acid domain
having a sequence of SEQ ID NO: 1. Alternatively, the
linker domain can have a different sequence from other
species having similar, conserved regions, including
sequences of SEQ ID NOS: 2-12.
The present invention, in another form, relates to the use
of novel compounds which include or mimic the functional
amino acid linker-domain from squalene synthase (SEQ ID
NO: 1) including but not limited to an amino acid sequence
ofSEQ ID NOS: 1-12 as a new class of compounds, such as
anti-infection agents, herbicides, etc., as provided by this
disclosure.
In addition, in one form or embodiment, the present
invention relates to new therapeutic agents and methods for
controlling cholesterol metabolism in humans using the
aforementioned compounds.
In yet an additional embodiment the present invention, a
method is provided for treating or controlling stern! biosyn
thesis by administering or applying a compound comprising
at least a portion of an amino acid linker-domain from
squalene synthase or a compound which mimics the physical
and chemical properties of this compound, to a subject, in
need of treatment, therefrom.
The present invention is based on prior studies in which
squalene synthase (erg9) deficient S. cerevisiae can be
complemented by the squalene synthase genes of various
fungi, but not those of plants or animals. However, the
specific mechanism behind this phenomenon has remained
eni gmatic. The present invention is further based on identifying a stretch of26 amino acids which is highly conserved
among fungal squalene synthases that does not affect cata
lytic activity of the enzyme yet is necessary and sufficient to
allow squalene synthase genes from any kingdom to
complement erg9 mutants of S. cerevisiae. Within this 26
amino acid domain, a stretch of four residues is almost
completely conserved among fungi, and when changed, the
yeast enzyme loses its ability to complement. These results
provide evidence that this domain is required for squalene
synthase to channel squalene into the stern! synthesis path
way. Overexpression of the non-catalytic C-terminal resi
dues of squalene synthase in S. cerevisiae prevents yeast
growth, but only when the fungal 26 amino acid linkerdomain is included. This confirms the importance of this
domain in substrate channeling and provides evidence that
molecules that mimic this domain as a new class of anti
fungal compounds, as well can be used new therapeutic
agents for the control of cholesterol metabolism in humans.
Further, due to the conservation of the amino acid linker
domain in squalene synthase fungal species, the linker
domain in the other fungal species can be used as a substitute
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for that of the 26 amino acid linker-domain, m vanous
embodiments of the present invention.
DESCRIPTION OF EXEMPLARY
EMBODIMENTS
Various embodiments of the present invention are based
on the inventor's discovery that specific portions of a full
length polypeptide/amino acid sequence for squalene syn
thase can complement a erg9 mutation in yeast. In particular,
it was discovered that an amino acid linker-domain from
squalene synthase can complement the erg9 mutation, to
restore squalene synthase activity. Based on this, compounds
were created which comprise the amino acid linker-domain
from squalene synthase. These compounds include peptides
which have the sequences of the linker-domain from natu
rally occurring organisms and can include those which
mimic the function and structure of the linker-domain.
In other embodiments, a method for treating or control
ling cholesterol metabolism in humans includes administer
ing a therapeutically effective amount of a compound com
prising at least a portion of an amino acid linker-domain
from squalene synthase, to a patient in need of treatment,
therefrom.
In other embodiments, a method is provided for treating
or controlling sterol biosynthesis by administering or apply
ing a compound comprising at least a portion of an amino
acid linker-domain from squalene synthase, to a subject, in
need of treatment, therefrom.
The present invention is based on specific examples and
experiments conducted as will be described below. Based on
those experiments and examples described below, the pres
ent Inventors discovered novel compounds that either
include an amino acid linker-domain of squalene synthase
from S. cerevisiae or have domains or characteristics that
mimic the amino acid linker-domain including but not
limited to the 26 amino acid linker sequence of SEQ ID NO:
1 as well as SEQ ID NOS: 2-12. For example, one of
ordinary skill in the art based on the present disclosure will
be able to identify other amino acid sequences which have
the desired physical and chemical properties to that of
compounds which include SEQ ID NO: 1. Further, the work
reported here describes the inventors' efforts to use the erg9
complementation test in yeast to map a specific peptide
domain within the carboxy-terminal region of the yeast
squalene synthase protein necessary for the complementa
tion phenotype.
Based on the experiments and results described below the
aforementioned compounds can be used or formulated into
anti-infection compounds such as antifungal compounds,
anti-parasitic compounds and herbicides. Further, the afore
mentioned compounds can be formulated as therapeutic
agents to control cholesterol metabolism in humans. In
addition, in accordance with the present disclosure, the
aforementioned compounds can be used in various methods
as antifungal compounds, anti-parasitic compounds and in
therapeutic treatments to control cholesterol metabolism,
ergosterol biosynthesis in fungi and other organisms depen
dent on ergosterol for viability.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth herein to facilitate explanation of the presently
disclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
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methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, refer
ence to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presently
disclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass varia
tions of in some embodiments±20%, in some embodi
ments±10%, in some embodiments±5%, in some embodi
ments±!%, in some embodiments±0.5%, and in some
embodiments±0.1 % from the specified amount, as such
variations are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
In some embodiments of the presently-disclosed subject
matter, pharmaceutical compositions comprise a portion of
an amino acid linker domain from squalene synthase. The
pharmaceutical composition may be included with a phar
maceutically-acceptable vehicle, carrier, or excipient. In
some embodiments, the pharmaceutical composition is phar
maceutically-acceptable in humans. Also, as described fur
ther below, in some embodiments, the pharmaceutical com
position can be formulated as a therapeutic composition for
delivery to a subject.
A pharmaceutical composition as described herein pref
erably comprises a composition that includes a pharmaceu
tical carrier such as aqueous and non-aqueous sterile injec
tion solutions that can contain antioxidants, buffers,
bacteriostats, bactericidal antibiotics and solutes that render
the formulation isotonic with the bodily fluids of the
intended recipient; and aqueous and non-aqueous sterile
suspensions, which can include suspending agents and
thickening agents. The pharmaceutical compositions used
can take such forms as suspensions, solutions or emulsions
in oily or aqueous vehicles, and can contain formulatory
agents such as suspending, stabilizing and/or dispersing
agents. Additionally, the formulations can be presented in
unit-dose or multi-dose containers, for example sealed
ampoules and vials, and can be stored in a frozen or
freeze-dried or room temperature (lyophilized) condition
requiring only the addition of sterile liquid carrier immedi
ately prior to use.
In some embodiments, solid formulations of the compo
sitions for oral administration can contain suitable carriers or
excipients, such as corn starch, gelatin, lactose, acacia,
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sucrose, microcrystalline cellulose, kaolin, mannitol, dical
cium phosphate, calcium carbonate, sodium chloride, or
alginic acid. Disintegrators that can be used include, but are
not limited to, microcrystalline cellulose, com starch,
sodium starch glycolate, and alginic acid. Tablet binders that
can be used include acacia, methylcellulose, sodium car
boxymethylcellulose, polyvinylpyrrolidone, hydroxypropyl
methylcellulose, sucrose, starch, and ethylcellulose. Lubri
cants that can be used include magnesium stearates, stearic
acid, silicone fluid, talc, waxes, oils, and colloidal silica.
Further, the solid formulations can be uncoated or they can
be coated by known techniques to delay disintegration and
absorption in the gastrointestinal tract and thereby provide a
sustained/extended action over a longer period of time. For
example, glyceryl monostearate or glyceryl distearate can be
employed to provide a sustained-/extended-release formu
lation. Numerous techniques for formulating sustained
release preparations are known to those of ordinary skill in
the art and can be used in accordance with the present
invention, including the techniques described in the follow
ing references: U.S. Pat. Nos. 4,891,223; 6,004,582; 5,397,
574; 5,419,917; 5,458,005; 5,458,887; 5,458,888; 5,472,
708; 6,106,862; 6,103,263; 6,099,862; 6,099,859; 6,096,
340; 6,077,541; 5,916,595; 5,837,379; 5,834,023; 5,885,
616; 5,456,921; 5,603,956; 5,512,297; 5,399,362; 5,399,
359; 5,399,358; 5,725,883; 5,773,025; 6,110,498; 5,952,
004; 5,912,013; 5,897,876; 5,824,638; 5,464,633; 5,422,
123; and 4,839,177; and WO 98/47491, each of which is
incorporated herein by this reference.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid
preparations can be prepared by conventional techniques
with pharmaceutically-acceptable additives such as sus
pending agents (e.g., sorbitol syrup, cellulose derivatives or
hydrogenated edible fats); emulsifying agents (e.g. lecithin
or acacia); non-aqueous vehicles (e.g., almond oil, oily
esters, ethyl alcohol or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or
sorbic acid). The preparations can also contain buffer salts,
flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be suitably formu
lated to give controlled release of the active compound. For
buccal administration, the compositions can take the form of
capsules, tablets or lozenges formulated in conventional
manner.
Various liquid and powder formulations can also be
prepared by conventional methods for inhalation into the
lungs of the subject to be treated or for intranasal adminis
tration into the nose and sinus cavities of a subject to be
treated. For example, the compositions can be conveniently
delivered in the form of an aerosol spray presentation from
pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluo
romethane, dichlorotetrafluoroethane, carbon dioxide, or
other suitable gas. Capsules and cartridges of, for example,
gelatin for use in an inhaler or insufllator may be formulated
containing a powder mix of the desired compound and a
suitable powder base such as lactose or starch.
The compositions can also be formulated as a preparation
for implantation or injection. Thus, for example, the com
positions can be formulated with suitable polymeric or
hydrophobic materials (e.g., as an emulsion in an acceptable
oil) or ion exchange resins, or as sparingly soluble deriva
tives (e.g., as a sparingly soluble salt).
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The compositions can further be formulated as topical
semi-sold ointment or cream formulations can contain a
concentration of the presently-described compositions in a
carrier such as a pharmaceutical cream base. Various for
mulations for topical use include drops, tinctures, lotions,
creams, solutions, and ointments containing the active ingre
dient and various supports and vehicles. The optimal per
centage of the therapeutic agent in each pharmaceutical
formulation varies according to the formulation itself and
the therapeutic effect desired in the specific pathologies and
correlated therapeutic. In some embodiments, such ointment
or cream formulations can be used for trans-dermal delivery
of the pharmaceutical compositions described herein or for
delivery to certain organs.
Injectable formulations of the compositions can contain
various carriers such as vegetable oils, dimethylacetamide,
dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl
myristate, ethanol, polyols (glycerol, propylene glycol, liq
uid polyethylene glycol), and the like. For intravenous
injections, water soluble versions of the compositions can be
administered by the drip method, whereby a formulation
including a pharmaceutical composition of the presently
disclosed subject matter and a physiologically-acceptable
excipient is infused. Physiologically-acceptable excipients
can include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular
preparations, e.g., a sterile formulation of a suitable soluble
salt form of the compounds, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injec
tion, 0.9% saline, or 5% glucose solution. A suitable
insoluble form of the composition can be prepared and
administered as a suspension in an aqueous base or a
pharmaceutically-acceptable oil base, such as an ester of a
long chain fatty acid, (e.g., ethyl oleate).
In addition to the formulations described above, compo
sitions comprising the amino acid linker domain of squalene
synthase or compounds which mimic this domain of the
presently-disclosed subject matter can also be formulated as
rectal compositions, such as suppositories or retention
enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides. Further, the present
compositions can also be formulated as a depot preparation
by combining the compositions with suitable polymeric or
hydrophobic materials (for example as an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.
For administration of a therapeutic composition as dis
closed herein (e.g., a composition comprising an amino acid
linker-domain from squalene synthase), conventional meth
ods of extrapolating human dosage based on doses admin
istered to a murine animal model can be carried out using the
conversion factor for converting the mouse dosage to human
dosage: Dose Human per kg=Dose Mouse per kgx12
(Freireich, et al., (1966) Cancer Chemother Rep. 50: 219244). Doses can also be given in milligrams per square meter
of body surface area because this method rather than body
weight achieves a good correlation to certain metabolic and
excretionary functions. Moreover, body surface area can be
used as a common denominator for drug dosage in adults
and children as well as in different animal species as
described by Freireich, et al. (Freireich et al., (1966) Cancer
Chemother Rep. 50:219-244). Briefly, to express a mg/kg
dose in any given species as the equivalent mg/sq m dose,
multiply the dose by the appropriate kg factor. In an adult
human, 100 mg/kg is equivalent to 100 mg/kgx37 kg/sq
m=3700 mg/m2.
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Suitable methods for administering a therapeutic compo
sition in accordance with the methods of the presently
SEQ ID NO:
Linker-Domain Sequence
disclosed subject matter include, but are not limited to,
KSKLAVQDPNFLKLNIQISKIEQFME
ScSS
systemic administration, parenteral administration (includ
160
AARMNAQDACYDRIEHLVNDAIRAME
TcSS
ing intravascular, intramuscular, and/or intraarterial admin
161
QKKLD VQDASSTSIANSLAAAIERID
LdSS
istration), oral delivery, buccal delivery, rectal delivery,
subcutaneous administration, intraperitoneal administration,
Since Tc and Ld have similar squalene synthase linker
inhalation, dermally (e.g., topical application), intratracheal
domain sequences to the squalene synthase linker-domain
installation, surgical implantation, transdermal delivery,
local injection, intranasal delivery, and hyper-velocity injec- 10 sequence in S. cerevisiae (as well as other organisms iden
tified in this disclosure, including FIG. 3, below), anti
tion/bombardment. Where applicable, continuous infusion
infection
agents can be formulated from compounds having
can enhance drug accumulation at a target site (see, e.g.,
at least a portion of an amino acid linker-domain from
U.S. Pat. No. 6,180,082). In some embodiments of the
squalene synthase. These formulated compounds can admintherapeutic methods described herein, the therapeutic com
positions are administered orally, intravenously, or intrap- 15 istered or applied to treat infections, which include fungal
and parasitic infections. The squalene synthase can have an
eritoneally to thereby treat a disease or disorder, as described
amino acid sequence of SEQ ID NOS: 1-12 and/or can have
herein below.
Regardless of the route of administration, the composi
a different sequence that mimics the physical and chemical
tions of the presently-disclosed subject matter typically not
properties of SEQ ID NOS: 1-12. The treatment can comonly include an effective amount of a therapeutic agent, but 20 prise administering a therapeutically effective amount of a
are typically administered in amount effective to achieve the
compound comprising at least a portion of an amino acid
desired response. As such, the term "effective amount" is
linker-domain from squalene synthase or one that mimics its
used herein to refer to an amount of the therapeutic com
physical and chemical properties, to a subject or patient in
need of treatment, therefrom.
position sufficient to produce a measurable biological
Still further provided, in some embodiments, are methods
response. Actual dosage levels of active ingredients in a 25
for treating or controlling cholesterol metabolism in humans
therapeutic composition of the presently-disclosed subject
by administering a therapeutically effective amount of a
matter can be varied so as to administer an amount of the
compound comprising at least a portion of an amino acid
active compound(s) that is effective to achieve the desired
linker-domain from squalene synthase, to a patient in need
therapeutic response for a particular subject and/or applica
tion. Of course, the effective amount in any particular case 30 of treatment, therefrom. In some embodiments, a method for
treating or controlling cholesterol metabolism in humans
will depend upon a variety of factors including the activity
comprises administering to a subject in need thereof an
of the therapeutic composition, formulation, the route of
effective amount of a compound comprising a polypeptide
administration, combination with other drugs or treatments,
having a sequence of SEQ ID NOS: 1-12 or a polypeptide
severity of the condition being treated, and the physical
condition and prior medical history of the subject being 35 which mimics its physical and chemical properties and
function.
treated. Preferably, a minimal dose is administered, and the
It will be appreciated that the function of the linker
dose is escalated in the absence of dose-limiting toxicity to
domain includes being able to complement an erg9 mutation
a minimally effective amount. Determination and adjust
in yeast. Further function includes restoring, in part,
ment of a therapeutically effective dose, as well as evalua
tion of when and how to make such adjustments, are known 40 squalene synthases activity in erg9 mutant yeast. Accord
ingly, a compound consisting essentially of a least a portion
to those of ordinary skill in the art.
of an amino acid linker-domain from squalene, in accor
For additional guidance regarding formulation and dose,
dance with some embodiments of the presently-disclosed
see U.S. Pat. Nos. 5,326,902; 5,234,933; PCT International
subject matter will be the compound having the aforemenPublication No. WO 93/25521; Berkow et al., (1997) The
Merck Manual of Medical Information, Home ed. Merck 45 tioned linker-domain and any other portion or modification
that does not materially affect the function of the compound.
Research Laboratories, Whitehouse Station, New Jersey;
As used herein, the terms "treatment" or "treating" relate
Goodman et al., (1996) Goodman & Gilman's the Pharma
to any treatment of a condition of interest (e.g. controlling
cological Basis of Therapeutics, 9th ed. McGraw-Hill
cholesterol metabolism), including but not limited to proHealth Professions Division, New York; Ebadi, (1998) CRC
Desk Reference of Clinical Pharmacology. CRC Press, Boca 50 phylactic treatment and therapeutic treatment. As such, the
terms "treatment" or "treating" include, but are not limited
Raton, Fla.; Katzung, (2001) Basic & Clinical Pharmacol
to: preventing a condition of interest or the development of
ogy, 8th ed. Lange Medical Books/McGraw-Hill Medical
a condition of interest; inhibiting the progression of a
Pub. Division, New York; Remington et al., (1975) Rem
condition of interest; arresting or preventing the further
ington's Pharmaceutical Sciences, 15th ed. Mack Pub. Co.,
Easton, Pa.; and Speight et al., (1997) Avery's Drug Treat 55 development of a condition of interest; reducing the severity
of a condition of interest; ameliorating or relieving symp
ment: A Guide to the Properties, Choice, Therapeutic Use
toms associated with a condition of interest; and causing a
and Economic Value of Drugs in Disease Management, 4th
regression of a condition of interest or one or more of the
ed. Adis International, Auckland/Philadelphia; Duch et al.,
symptoms associated with a condition of interest.
(1998) Toxicol. Lett. 100-101:255-263.
Yet further provided, in some embodiments, are methods 60
As used herein, the term "subject" includes human, animal and plant subjects. Thus, veterinary therapeutic uses are
for treating infections including fungal and non-fungal
infections, e.g. parasitic infections. Examples of parasitic
provided in accordance with the presently-disclosed subject
infections treated include trypanosomatid infections such as
matter. As such, the presently-disclosed subject matter pro
vides for the treatment of mammals such as humans, as well
those caused by trypanosoma cruzi (Tc) and Leishmania
donovani (Ld). Tc and Ld have similar squalene synthase 65 as those mammals of importance due to being endangered,
linker-domains (TcSS and LdSS, respectively) to that for S.
such as Siberian tigers; of economic importance, such as
cerevisiae (ScSS) as shown in the table below:
animals raised on farms for consumption by humans; and/or
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animals of social importance to humans, such as animals
kept as pets or in zoos. Examples ofsuch animals include but
are not limited to: carnivores such as cats and dogs; swine,
including pigs, hogs, and wild boars; ruminants and/or
ungulates such as cattle, oxen, sheep, giraffes, deer, goats,
bison, and camels; and horses. Also provided is the treat
ment ofbirds, including the treatment ofthose kinds ofbirds
that are endangered and/or kept in zoos, as well as fowl, and
more particularly domesticated fowl, i.e., poultry, such as
turkeys, chickens, ducks, geese, guinea fowl, and the like, as
they are also of economic importance to humans. Thus, also
provided is the treatment of livestock, including, but not
limited to, domesticated swine, ruminants, ungulates, horses
(including race horses), poultry, and the like.
The practice of the presently-disclosed subject matter can
employ, unless otherwise indicated, conventional techniques
of cell biology, cell culture, molecular biology, transgenic
biology, microbiology, recombinant DNA, and immunology,
which are within the skill of the art. Such techniques are
explained fully in the literature. See e.g., Molecular Cloning
A Laboratory Manual (1989), 2nd Ed., ed. by Sambrook,
Fritsch and Maniatis, eds., Cold Spring Harbor Laboratory
Press, Chapters 16 and 17; U.S. Pat. No. 4,683,195; DNA
Cloning, Volumes I and II, Glover, ed., 1985; Oligonucle
otide Synthesis, M. J. Gait, ed., 1984; Nucleic Acid Hybridization, D. Hames & S. J. Higgins, eds., 1984; Transcription
and Translation, B. D. Hames & S. J. Higgins, eds., 1984;
Culture OfAnimal Cells, R. I. Freshney, Alan R. Liss, Inc.,
1987; Immobilized Cells And Enzymes, IRL Press, 1986;
Perbal (1984), A Practical Guide To Molecular Cloning; See
Methods In Enzymology (Academic Press, Inc., N.Y.); Gene
Transfer Vectors For Mammalian Cells, J. H. Miller and M.
P. Calos, eds., Cold Spring Harbor Laboratory, 1987; Meth
ods In Enzymology, Vols. 154 and 155, Wu et al., eds.,
Academic Press Inc., N.Y.; Immunochemical Methods In
Cell And Molecular Biology (Mayer and Walker, eds.,
Academic Press, London, 1987; Handbook OfExperimental
Immunology, Volumes I-IV, D. M. Weir and C. C. Black
well, eds., 1986.
EXPERIMENTS AND EXAMPLES
The details ofone or more embodiments of the presently
disclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exem
plary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case ofconflict, the specification of
this document, including definitions, will control.
The following results of experiments and examples pro
vide evidence of efficacy and generation of the aforementioned compounds and therapeutic treatments. These experi
ments and examples are intended to be non-limiting, and
illustrate only certain embodiments ofthe present invention.
Furthermore, the examples and experiments may include
compilations of data that are representative of data gathered
at various times during the course of development and
experimentation related to the presently-disclosed subject
matter.
Complementing the erg9 knockout mutation in yeast
requires more than active squalene synthase enzyme activity
and squalene accumulation. The following discussion
describes the process used to develop a complementing
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compound to restore squalene synthase actively in erg9
knockout mutation yeast and thereby lead to novel com
pounds, e.g. proteins/peptides.
Various squalene synthases were cloned into the yeast
expression vector, Yep352-ADH1, including those from S.
cerevisiae (YSS), B. braunii (BSS), N. benthamiana (TSS),
A. thaliana (ASS), and R. norvegicus (RSS), as well as a
C-terminal truncated form ofYSS in which 24 amino acids
comprising the ER membrane-spanning region were elimi
nated (YSStr). These constructs were transformed into the
yeast line CALI7-1, which has been selected for high level
FPP biosynthesis (10) and has an erg9 knockout mutation. It
is unable to synthesize sterols de nova and is dependent on
exogenous ergosterol for growth. To test if introducing the
various squalene synthases could restore ergosterol proto
trophy to CALI7-1 yeast line, colonies testing positive for
the respective SS transgene by PCR screens were grown in
selection media containing ergosterol and serial dilutions
were spotted on plates not containing exogenous ergosterol
(FIG. 1). To evaluate the encoded enzymes for catalytic
activity, extracts prepared from the CALI7-1 yeast lines
were assayed for squalene synthase enzyme activity. Con
structs were also expressed in TN-7 yeast line and cultures
were grown in liquid media with ergosterol and subse
quently analyzed for squalene accumulation. Squalene lev
els were determined in TN-7 because in this yeast line, there
is no possibility of squalene feeding into the ergosterol
biosynthetic pathway. This allows for accurate comparisons
of squalene production by the various SS enzymes.
Interestingly, only the full-length YSS gene and a car
boxy-terminal truncated form (deletion of the terminal 24
amino acids) could restore ergosterol prototrophy to the
Cali7-1 yeast line. Further, significant squalene accumula
tion and SS enzyme activity was observed in all squalene
synthase constructs tested, providing evidence that the
enzyme was properly expressed in an active form in all cases
(FIG. 1). This provides evidence that all SS enzymes tested
properly expressed in vivo, but only YSS could complement
the erg9 deficient CALI7-1 yeast line.
The terminal membrane-spanning domain of squalene
synthase is not necessary for functional enzyme nor comple
mentation of the erg9 mutant.
To corroborate and extend the earlier observations of
Kirbii et al (7) that a non-catalytic, carboxy-terminal domain
was important for complementation, reciprocal molecular
swaps ofthe terminal 100 or so amino acids of various plant
and algae SS enzymes were created with that corresponding
to the 91 carboxy-terminal amino acids from S. cerevisiae
SS and tested each for its ability to complement the erg9
mutation in yeast line CALI7-1 (FIG. 2). As expected, all the
constructs that contained the carboxy-terminus of S. cerevi
siae SS were able to complement the erg9 knockout muta
tion in Cali7-1, while none of the S. cerevisiae SS enzymes
that had their carboxy-terminus replaced with that ofa plant
or algae SS displayed ergosterol prototrophy.
Of equal interest is the observation that constructs con
taining a deletion ofthe terminal 24 amino acids ofthe yeast
SS (YSStr, FIG. 1) or appending this modified terminal
domain to the algal SS (BSS-YSStr, FIG. 2) did not alter the
ability of these gene constructs to complement the erg9
deletion. On the basis of hydropathy plots of this region of
the SS enzymes (3), this terminal region has been referred to
as a membrane-spanning domain and by inference the
domain mediating tethering ofthe SS enzyme activity to the
ER membrane system in eukaryotic cells (3). Regardless of
these inferences, the YSStr and BSS-YSStr constructs
shown in FIGS. 1 and 2 encode for functionally soluble SS
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enzyme activity (enzyme activity found in 20,000 g super
natants ofE. coli expressing this genes) and these constructs
complemented the erg9 mutation in yeast equally well as the
full-length gene constructs. Hence, the carboxy-terminal 24
amino acids of the yeast SS are not necessary for the
complementation phenotype, but some other element(s)
within the proximal 67 amino acids of the carboxy-terminus
appears to be both necessary and sufficient for complemen
tation.
Computational screens for possible carboxy terminal
domains responsible for the complementation phenotype.
Because squalene synthase genes from S. cerevisiae (this
disclosure), S. pombe (3), and Y. lipolytica (8) have been
demonstrated to complement the erg9 knockout in yeast, but
squalene synthases from plant, algae and animals carmot,
and because the results in FIGS. 1 and 2 pointed to a
proximal carboxy terminal region of 67 amino acids being
responsible for the specificity of this complementation,
amino acid sequence comparisons of this region between
relevant squalene synthases were performed. No over-arching sequence similarities were observed when comparing the
sequences across this region from algae, plants, animals and
fungi, although there were greater similarities within the first
26 amino acids of this region (FIG. 3, bottom portion "B").
This degree of similarity became much more apparent when
the alignments of only the fungal squalene synthase were
compared (FIG. 3, top portion "A"). Within this short
segment of amino acids, 8 residues are absolutely conserved
and the degree of amino acid similarity across the entire 26
amino acids reaches upwards of 45%.
To functionally evaluate the contribution of this domain to
the complementation phenotype, reciprocal constructs
where these 26 amino acids ofYSS were exchanged with the
corresponding amino acids regions within the BSS and ASS
were generated. These constructs were transformed into the
erg9 knockout yeast line, and 3 independent colonies from
each transformation were screened for their ability to grow
in the absence of ergosterol (FIG. 4). When the carboxy
terminal 26 amino acid sequence from S. cerevisae was
substituted into the algal (BSS-YSS-BSS), complementation
was readily apparent. When the carboxy-terminal 26 amino
acid sequence from S. cerevisae was substituted into the
Arabidopsis backbone (ASS-YSS-ASS), complementation
was restored but the growth rate was noticeably affected.
Further analysis revealed that squalene accumulation in this
yeast line was only about 5% that of the wild type YSS.
Further, squalene synthase enzyme activity in this yeast line
was only 7.6% the level as the YSS-expressing yeast line.
This provides evidence that the ASS-YSS-ASS was com
promised in its squalene synthase enzyme activity, but was
still able to complement the erg9 knockout. The reciprocal
substitutions of inserting the algal or plant amino acid
sequences into the corresponding site of the S. cerevisiae SS
resulted in a loss of its ability to complement the erg9
knockout mutations. The loss of this complementation capability was not due to a loss in the catalytic activity of the
yeast SS. When these lines were grown in the presence of
ergosterol, greater levels of squalene accumulated in these
cultures relative to those lines transformed with the wild
type YSS construct or other erg9 complementing constructs
and SS enzyme activity could be readily measured in yeast
lysates.
Mapping the specific amino acids contributing to the
complementation phenotype.
To further assess the contribution of individual amino
acids within this key stretch of 26 amino acids, fine mapping
substitution series constructs were generated (FIG. 5). First,
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mutants were created in which either the first half (13
residues) or the second half of the 26 amino acid domain was
swapped from the A. thaliana SS into the S. cerevisiae
backbone (FIG. 5, mutants a and b). Swapping out the first
13 amino acids of the S. cerevisiae SS (FIG. 5, mutant a) had
no effect on the ability of the subsequent construct to
complement the erg9 mutation, but swapping the second half
resulted in a complete loss of the complementation phenotype (FIG. 5, mutant b). Swapping out the first 13 amino
acids of A. thaliana SS with those in S. cerevisiae also had
no effect on the ability of this construct to complement the
erg9 mutant (FIG. 5, mutant f). However, exchanging the
second half of these residues with those of the yeast squalene
synthase enabled the construct to restore partial growth to
the erg9 mutant (FIG. 5, mutant g). Thus, it appeared that the
residues in the second half of the 26-amino acid domain
were largely responsible for complementation phenotype
and this stretch of amino acids was evaluated further.
Because the KIEQ (SEQ ID NO: 35) and FLKLNIQ
(SEQ ID NO: 36) stretches of amino acids seem particularly
conserved amongst the fungal squalene synthases, various
combinations of these peptide domains were exchanged
between the ASS and YSS constructs (FIG. 5, mutants c-e
and h-j). When the "FLKLNIQ" (SEQ ID NO: 36) stretch of
YSS was replaced with the corresponding domain of ASS
(FIG. 5, mutant d), complementation growth was not
affected, and likewise the reciprocal swap in ASS (FIG. 5,
mutant i) did not restore complementation. However, when
the "KIEQ" (SEQ ID NO: 35) stretch ofYSS was replaced
with the corresponding domain of ASS (FIG. 5, mutant c),
growth of the yeast was significantly impaired, suggesting
that complementation had been affected. The reciprocal
swap in ASS (FIG. 5, mutant h) did not restore growth of the
erg9 mutant. Two additional mutants in which the entire
domains spanning from "FLKLNIQ" (SEQ ID NO: 36) to
"KIEQ" (SEQ ID NO: 35) were exchanged (FIG. 5, mutant
e and j) were also evaluated for their ability to complement
the erg9 mutation. Consistent with our expectations from the
other mutants, substituting the yeast amino acids of this
domain with those from the Arabidopsis squalene synthase
resulted in a complete lose in the ability of this construct to
complete the erg9 mutation. However, unexpectedly, sub
stitution of this domain in the Arabidopsis squalene synthase
gene with that of the yeast squalene synthase only restored
a very modest level of growth to mutant yeast in the
complementation tests. All constructs tested in FIG. 5, when
expressed in yeast, accumulated higher levels of squalene
and had SS enzyme activity in excess of yeast expressing
YSS.
The membrane spanning, carboxy-terminal sequence is
responsible for localizing squalene synthase to a common
membrane system.
One possible explanation for the uniqueness of the car
boxy-terminal domains would be that the plant carboxy
termini would target the squalene synthase enzyme to a
different intracellular compartment than the yeast carboxy
terminus. To evaluate this possibility, DNA coding for
different fluorescent tags were appended to the 5' end of the
yeast, plant or chimera squalene synthase gene and these
were co-expressed in yeast. The subsequent transformants
were then subjected to confocal microscopy to visualize the
intracellular distribution of each protein. If the yeast
squalene synthase carboxy terminus were to direct proteins
to a local different from the plant carboxy terminus, then
superimposition of the fluorescent images would not be
expected to overlap and distinct red and green colors would
be visible. Instead, co-localization should result in over-
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lapping images and color blending (green over-lapping with
red) would yield a yellow image. FIG. 6 represents, in gray
scale, rather than color (red/green), that the latter indeed
occurs, providing strong evidence that the significance of the
26 amino acid linker domain is not to provide a distinct
cellular localization signal.
Over-expression of the 26 amino acid linker domain
serves to inhibit fungal growth.
If the fungal 26 amino acid sequence was providing for
specific and unique interactions between squalene synthase
and some other factor(s), thus providing for prototrophic
production of endogenous sterols, then over-expression of
this peptide fragment might be expected to disrupt normal
stern! metabolism and hence disrupt fungal growth. To test
this possibility, a gene coding for the 92 carboxy terminal
residues of the yeast squalene synthase was inserted into a
galactose inducible expression vector and the recombinant
vector introduced into a wild type yeast (BY4741) (FIG. 7).
When grown on glucose, expression of the 92 carboxy
terminal squalene synthase gene was suppressed and the
transformed yeast grew normally. However, when the same
transformants were grown on galactose, growth was
severely arrested. If a plant complementary carboxy-termi
nal gene was substituted for the yeast, no adverse effects
were noted. When the 26 amino acid linker domain was
deleted from the yeast gene construct, growth also was not
impaired. When the deleted region was replaced with the
correspond domain from a plant (ASS-YSS) or algae (BSS
Y SS), growth also was unaffected. However, if the yeast 26
amino acid linker domain was substitute for the correspond
ing region of the plant (Y SS-ASS) or algal (YSS-BSS) gene,
then growth was abolished under conditions of induction of
gene expression (plus galactose).
The 26 amino acid linker domain is unique to each
kingdom, and hence represents a target for kingdom specific
control of stern! metabolism.
Attention to the 26 amino acid linker domain came about
because of its unique conservation within fungal squalene
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distinctly different between kingdoms. FIG. 8 provides a
phylogenetic assessment of this domain between the king
doms of plants, animals and fungi and shows distinct clus
tering of these domains within squalene synthase genes to
clades representing only organisms reflecting each of the
kingdoms. Hence, one would expect that disruption of the 26
amino acid linker domain within mammalian cells to also
disrupt cholesterol metabolism, much like we have observed
for fungi.
Materials and Methods
The following disclosure provides background to the
parameters and the experimental conditions used to generate
the results discussed above.
Cloning the Various Squalene Synthases
Squalene synthases from S. cerevisiae (YSS), B. braunii
(BSS), R. norvegicus (RSS), N. benthamiana (T SS), and A.
thaliana (ASS) were cloned from original cell or tissue
sources. First, total RNA was isolated from the respective
species using the RNeasy Plant mini kit (Qiagen) or Trizol
(Invitrogen, for R. norvegicus and S. cerevisiae) according
to the manufacturer's recommendations, and first strand
cDNA was synthesized using the SMARTer PCR cDNA
synthesis kit (Clontech). The first strand cDNA was used as
a template to amplify the various squalene synthase genes
using the primer sets listed in Table 1 (restriction site in
bold). Y SS was cloned into the Yep352 vector with the Asel
and XbaI sites, and a 3'-truncated form cloned into Yep352
and pET28a using the Asel and XbaI or BamHI and XhoI
sites, respectively. BSS was cloned into Yep352 with the
EcoRI and HindIII sites. RSS was cloned into Y Ep352 using
the EcoRI and Natl sites and a 5'- and 3'-truncated RSS was
cloned into pET28a using the BamHI and XhoI sites. T SS
was cloned into Yep352 with the EcoRI and Natl sites. ASS
was cloned into Yep352 with the EcoRI and Natl sites. All
constructs were verified by automated DNA sequencing.
TABLE 1
Sgualene Synthase Primer Seguences.

gene

primer

YSS

Asel For
BamHI For
Xbal Rev
Not! Rev
Xbal Rev trune
Xhol Rev trune
Notl Rev trune
BSS EeoRI For
HindIII Rev
Not! Rev
RSS EeoRI For
BamHI For trune
Not! Rev
Xhol Rev trune
TSS EeoRI For
Xbal Rev
Not! Rev
ASS EeoRI For
Xbal Rev
Not! Rev

synthases (FIG. 3). If this were to be a universal feature of
squalene synthases, then one would expect this corresponding domain in plant and animal squalene synthases to be
highly conserved within that kingdom of organisms, and

Sequence

AGGCGCGCCAAAACAATGGGAAAGCTATTACAATGGC
CGCGGATCCAAAACAATGGGAAAGCTATTACAATGGC
GCTCTAGATCACGCTCTGTGTAAAGTGTATAT
ATAAGAATGCGGCCGCTCACGCTCTGTGTAAAGTG
GCTCTAGATCACTTGTACTCTTCTTC
GGGCTCGAGTCACTTGTACTCTTCTTC
ATAAGAATGCGGCCGCTCACTTGTACTCTTCTTCTTG
CCGGAATTCAAAACAATGGGGATGCTTCGCTGGGGAGTGG
ATCCCAAGCTTTTAGGCGCTGAGTGTGGGTCTAGG
ATAAGAATGCGGCCGCTTAGGCGCTGAGTGTGGGTCTAGG
GGAATTCAAAACAATGGAGTTCGTGAAGTGTCTAGGCC
CGCGGATCCATGGACCGGAACTCGCTCAGC
ATAAGAATGCGGCCGCTCAGTGTTCTCTCTGGACATAGTC
CCGCTCGAGTCAGCTCTGCGTCCTGATGTTGGAG
GGAATTCATGGGGAGTTTGAGGGCTATTC
GCTCTAGACTAAGATCGGTTTCCGGATAGC
ATAAGAATGCGGCCGCCTAAGATCGGTTTCCGGATAGC
CCGGAATTCAAAACAATGGGGAGCTTGGGGACGATGCTG
GCTCTAGATCAGTTTGCTCTGAGATATGC
ATAAGAATGCGGCCGCTCAGTTTGCTCTGAGATATGCAAAG

65

SEQ
IDNO.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Creating the BSS-YSS fusion
A reverse primer was designed to pair with the BSS EcoRI
For (see Table 1), to amplify the first 352 codons of BSS
except that a single nucleotide mutation was introduced into
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the 35rd codon to introduce a HindIII restriction site
without changing the encoded amino acid (ATCCC
�GCTTCTCTGCTAATTTGAGG (SEQ ID NO: 57), Hin
dIII site in bold, mutation underlined). This was cloned into
the pET28a vector with the corresponding restriction sites,
giving BSS 352-pET28a. Another primer was designed to pair
with either primer, YSS Natl Rev or YSS Natl Rev trunc, to
amplify YSS starting from codon 353 (ATCCAAGCT
TAAATCTAAATTGGCTGTGC (SEQ ID NO: 58), HindIII
site in bold), and these fragments cloned into BSS352pET28a cut with HindIII and Natl to give the BSS-YSS and
BSS-YSStr constructs. These were cut from the pET28a
vector using EcoRI and Natl and ligated into the corre
sponding sites of Yep352. The construct was verified by
automated DNA sequencing.
Creating the BSS-YSS-BSS Expression Cassette
A primer was designed to pair with primer, BSS EcoRI
For, to amplify a fragment of the BSS-YSS construct with
NgoMIV and Natl restriction sites (ATAAAGAATGCGGC
CGCGAATGCCGGCTTCCATAAACTGTTCGATCTTGG
(SEQ ID NO: 59), NgoMIV and Natl sites in bold). This was
cloned into the EcoRI and Natl sites of YEp352, which was
later cut with NgoMIV and Natl. Meanwhile a primer was
designed to pair with primer, BSS Natl Rev, to amplify a 3'
region of BSS except that two nucleotide mutations were
introduced to add an NgoMIV restriction site without chang
ing the encoded amino acids (GCAAAGAATGC�GG
�CTGGCACGCACAAAAGATGACACC (SEQ ID NO:
60), NgoMIV site in bold, mutations underlined). This
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fragment was cloned into the NgoMIV and Natl sites of the
cut Yep352 vector to give BSS-YSS-BSS. The construct was
verified by automated DNA sequencing.
Creating Other Fusion Constructs
All other fusion constructs were created by employing an
assembly PCR strategy as described by Niehaus et al. (11 ),
using the primers listed in Tables 1 and 2. For example,
YSS-BSS was created by using YSS as a template with the
primer set, YSS-BSS IR and YSS Asel For, to amplify a
fragment of YSS with a 3' overhang, and using BSS as the
template with the primer set, YSS-BSS IF and BSS HindIII
Rev, to amplify a fragment of BSS with a 5' overhang. These
two fragments were both used as templates in a PCR
reaction with the primer set, YSS Asel For and BSS HindIII
Rev, to give the YSS-BSS construct, which was cloned into
the YEp352 vector with the corresponding restriction sites.
YSS-BSS-YSS was created by using YSS-BSS and YSS as
templates in the initial PCR reaction, and cloning the fin
ished construct into YEp352 with the Asel and Xbal sites.
All other constructs were created in a similar mamier.
TSS-YSS and YSS-TSS were cloned into YEp352 with the
EcoRI and Natl, or Asel and Xbal restriction sites, respec
tively. YSS-ASS and ASS-YSS were cloned into YEp352
with Asel and Xbal, or EcoRI and Xbal restriction sites,
respectively. All YSS M( a)-M( e) constructs were cloned into
YEp352 with the Asel and Xbal restriction sites, and all ASS
M(f)-M(j) constructs were cloned into YEp352 with EcoRI
and Xbal restriction sites. All constructs were verified by
automated DNA sequencing.
TABLE 2

Chimeric Sgualene Synthase Primer Sequences.

SEQ
construct

direction sequence

lF
lR
lF
YSS-ASS
lR
lF
ASS-YSS
lR
lF
YSS-TSS
lR
TSS-YSS
lF
lR
YSS-BSS-YSS lF
lR
YSS-ASS-YSS lF
lR
ASS-YSS-ASS lF
lR
YSS M(c)
lF
lR
lF
YSS M(d)
lR
lF
YSS M(e)
lR
YSS M(a)
lF
lR
lF
YSS M(b)
lR
lF
ASS M(h)
lR
ASS M(i)
lF
lR
lF
ASS M(j)
lR
lF
ASS M(f)
lR
ASS M(g)
lF
lR
YSS-BSS

CTTACGTGATATCGAAGTCAGATGCAACACCGAGACCAGCGAGGATCCC
GCATCTGACTTCGATATCACGTAAGTAATAGTCAAAAATCTCGACACAGCC
CTTACGTGATATCAAGACAAAGGTTGACAAGAACGATCCAAATGCCAG
CAACCTTTGTCTTGATATCACGTAAGTAATAGTCAAAAATCTCGACAC
CCTGCATGCTGAAATCTAAATTGGCTGTGCAAGATCCAAATTTCTTA
GCCAATTTAGATTTCAGCATGCAGGAAAAATCATAGAAAGCACCATAG
CTTACGTGATATCAAATCCAAGGTTAATAATAATGATCCAAATGCAAC
TTAACCTTGGATTTGATATCACGTAAGTAATAGTCAAAAATCTCGACAC
GACTITTCTIGTATGCTGAAATCTAAATTGGCTGTGCAAGATCCAAATTICTT
GCCAATTTAGATTICAGCATACAAGAAAAGICAAAAAAAGCACCATATACATC
CAAAGCTGCCTGCAAGGAAATGTACCAGGATAAATTACCTCCTAACGTGAAGCC
CCTGGTACATTTCCTTGCAGGCAGCTTTGATCTTATGCAGGTGTTCCAGAG
AAGACAAAGGTTGACAAGAACGATCCAAATGCCAGTAAGACACTAAACCGACTTGAAGCC
TCTGCAGAGTTTCTGAACGGCTTCAAGTCGGTTTAGTGTCTTACTGGCATTTGGATCGTT
AAATCTAAATTGGCTGTGCAAGATCCAAATTICTTAAAATTGAACATTCAAATCTCCAAG
TTCCATAAACTGITCGATCTIGGAGATTTGAATGITCAATITTAAGAAATTIGGATCTIG
CTCCGCCGTTCAAAAGTTTATGGAAGAAATGTACCAGGATAAATTACC
CCATAAACTTTTGAACGGCGGAGATTTGAATGTTCAATTTTAAG
AATGCCAGTAAGACACTAAACCGTATCTCCAAGATCGAACAGTTTATGG
GATACGGTTTAGTGTCTTACTGGCATTTGGATCTTGCACAGCCAATTTAG
GCCAGTAAGACACTAAACCGTCTTGAAGCCGTTCAGAAGTTTATGGAAGAAATGTACCAG
CTTCTGAACGGCTTCAAGACGGTTTAGTGTCTTACTGGCATTTGGATCTTGCACAGCC
AAGACAAAGGTTGACAAGAACGATCCAAATGCCAGTAAGTTGAACATTCAAATCTCCAAG
CTTACTGGCATTTGGATCGTTCTTGTCAACCTTTGTCTTGATATCACGTAAGTAATAGTC
ACACTAAACCGACTTGAAGCCGTTCAGAAACTCTGCAGAGAAATGTACCAGGATAAATTA
TCTGCAGAGTTTCTGAACGGCTTCAAGTCGGTTTAGTGTTTTTAAGAAATTTGGATCTTG
CTTGAAAAGATCGAACAGCTCTGCAGAGACGCTGGAGTTCTTC
CAGAGCTGTTCGATCTTTTCAAGTCGGTTTAGTGTCTTACTGGC
AATTICTTAAAATTGAACATTCAACTTGAAGCCGTICAGAAACTCTGCAG
AAGTTGAATGTTCAATTTTAAGAAATTTGGATCGTTCTTGTCAACCTTTG
TICTTAAAATTGAACATTCAAATCTCCAAGATCGAACAGCTCTGCAGAGACGCTGGAG
CTGTTCGATCTTGGAGATTTGAATGTTCAATTTTAAGAAATTTGGATCGTTCTTGTCAAC
AAATCTAAATTGGCTGTGCAAGATCCAAATTICTTAAAAACACTAAACCGACTTGAAGCC
TITTAAGAAATTIGGATCTTGCACAGCCAATTTAGATTICAGCATGCAGGAAAAATCATA
TTGAACATTCAAATCTCCAAGATCGAACAGITTATGGAAGACGCTGGAGTICTICAAAAC
TTCCATAAACTGITCGATCTIGGAGATTTGAATGITCAACTTACTGGCATTIGGATCGTT

ID
NO.
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
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The Erg9 Complementation Assay
The Cali7-1 yeast line, which has an erg9 deletion so that
it cannot synthesize sterols de nova and requires exogenous
ergosterol for growth, was used for these purposes (10). The
various squalene synthase constructs were transformed into
Cali7-1 yeast using the lithium acetate method and plated on
Yeast Synthetic Drop-out medium (selection media) lacking
uracil and containing 5 mg/Iergosterol. Three independent
CALI7-1 transformants of each construct were randomly
selected and grown in 2 mL Yeast Synthetic Drop-out media
(Sigma) containing 5 mg/L ergosterol at 28° C. for three
days (OD600=6.0±0.3 after three days of growth), after
which the culture was serially diluted with water to optical
densities (600 nm) equal to 1, 0.2, 0.04, and 0.008, and 5 µL
of each dilution spotted onto Yeast Synthetic Drop-out
media plates without any exogenous ergosterol. Plates were
incubated at 28° C. for 72 hours.
Liquid cultures of each transformant in TN-7 line were
grown in 10 mL of Yeast Synthetic Drop-out media con
taining 5 mg/L ergosterol at room temperature for seven
days. Organic extracts were prepared and analyzed by
GC-MS for their squalene content. In brief, 1 mL aliquots of
the culture were combined with 1 mL of acetone, vigorously
mixed, and incubated at room temperature for 10 min. One
mL of hexane was added and mixed vigorously for 60 sec.
The mixture was then centrifuged briefly at 500xg to sepa
rate the phases, and an aliquot of the organic phase removed
and 1-2 µL aliquots analyzed by GC-MS with a Varian
CP-3800 GC coupled to a Varian Saturn 2200 MS/MS
(Varian Medical Systems) using a Supelco SLB-5 ms fused
silica capillary column (30 mx0.25 mmx0.25 µM film
thickness, Supelco). Initial oven temperature was set at 220°
C. for 1 min., ramped to 280° C. at 20° C./min., then ramped
to 300° C. at 3 ° C./min.
The various SS constructs were expressed in Cali-7 yeast
and grown for 3 days before 1.5 ml of culture was collected
by centrifugation and stored at -80 C until further analysis.
Yeast pellets were resuspended in 0.5 ml buffer (50 mM
NaH2P04, pH 7.8, 300 mM NaCl, 1 mM MgCl2, 1 mM
PMSF, 1% glycerol (v/v)) then sonicated 3x for 5 sec with
a microprobe sonicator at 60% maximum power. The
samples were cooled on ice for 2 min between sonication
treatments. The sonicate was centrifuged at 2,000 g for 10
min at 4 ° C. and the supernatant used in enzyme assays.
Assays contained 50 mM Mops, pH 7.3, 20 mM MgCl2, 2.5
mM 2-mercaptoethanol, 10 µM [1-3H]-FPP (-lx105 dpm
total), 2 mM NADPH, and 5 µL cell lysate in total reaction
volume of 50 µL. Reactions were incubated at 37° C. for 1
h and then extracted with 100 µIn-hexane and an aliqout
spotted on silica-TLC plates with a squalene standard. TLC
was developed with n-hexane and the squalene zone was
visualized with iodine vapor, scraped and analyzed by
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scintillation spectroscopy. The amount of total protein in the
yeast supernatants was determined by Bradford Dye assays.
Enzyme activity (pmole/h/µg total protein) is expressed as a
percent of S. cerevisiae squalene synthase (YSS) enzyme
activity. n= 3.
Creation and Expression of Fluorescent Protein Tagged
Constructs
An assembly PCR strategy (described above) was used to
create constructs in which either efGFP or DsRedl was
fused to the amino terminus of various squalene synthase
enzymes connected by a (GSGG)x2 peptide linker
sequence. Primers used to create these constructs are listed
in Table 3 (restriction sites, if any, in bold). For example,
efGFP-YSS was created by using efGFP as a template with
the primer set, efGFP Asel For and efGFP lr, to amplify the
efGFP coding sequence with a 3' overhanging linker
sequence, and using YSS as the template with the primer set,
efGFP-YSS if and YSS XbaI Rev, to amplify YSS with a 5'
overhanging linker sequence. These two fragments were
both used as templates in a PCR reaction with the primer set,
efGFP Asel For and YSS XbaI Rev, to give the efGFP-YSS
construct, which was cloned into YEp352 with the corre
sponding restriction sites. Similarly, efGFP-BYB was cre
ated by using efGFP as the template with the primer set,
efGFP Asel For and efGFP lr, and using BSS-YSS-BSS as
the template with the primer set, efGFP-BSS if and BSS
XbaI Rev, in the initial PCR reaction and cloning the
assembled product into YEp352 with the Asel and XbaI
sites. DsRedl-BSS was created using DsRedl as the template with the primer set, DsRedl XhoI For and DsRedl lr,
and using BSS as the template with the primer set, DsRedl
BSS if and BSS Natl Rev, in the initial PCR reaction and
cloning the assembled product into pESC-leu with the XhoI
and Natl sites. DsRedl-BSS was also cloned into the
YEp352 vector by amplifying the sequence with the primer
set, DsRedl Asel For and BSS XbaI Rev, and cloning into
the corresponding restriction sites. efGFP-YSStr was cre
ated by using efGFP-YSS as the template with the primer
set, efGFP Asel For and YSStr XbaI Rev, and cloning the
amplified product into the corresponding sites of YEp352.
All constructs were verified by automated DNA sequencing.
A CFP-tagged ER-marker (Pho86p) was kindly provided by
Dr. Peter Nagy (12).
Various combinations of fluorescent-tagged squalene synthases or a CFP-tagged ER marker were transformed into
Cali-7 yeast. Positive transformants were identified by PCR
screening and grown in Yeast-synthetic Drop-out media
containing 5 mg/L ergosterol for three days. Cells were
collected by brief centrifugation at 500xg and applied to
glass adhesion microscope slides. Confocal laser scanning
micrographs were acquired on an Olympus FV l000 micro
scope (Olympus America Inc., Melville, N.Y.).
TABLE 3

Fluorescence protein tagged squalene synthase construct primers
gene/construct

primer

sequence

efGFP
DsRedl
DsRedl
efGFP
DsRedl
efGFP-YSS
efGFP-BSS
DsRedl-BSS

Asel For
Xhol For
Asel For
lR
lR
lF
lF
lF

AGGCGCGCCAAAACAATGTCTAAAGGTGAAGAATTATTC
CCGCTCGAGAAAACAATGGTGCGCTCCTCCAAGAACGTC
AGGCGCGCCAAAACAATGGTGCGCTCCTCCAAGAACGTC
CATACCAGAACCACCACCAGAACCACCTTTGTACAATTCATCCATACCATGG
CATACCAGAACCACCACCAGAACCACCCAGGAACAGGTGGTGGCGGCCC
CAAAGGTGGTTCTGGTGGTGGTTCTGGTATGGGAAAGCTATTACAATTGGC
CAAAGGTGGTTCTGGTGGTGGTTCTGGTATGGGGATGCTTCGCTGGGGAGTGG
CCTGGGTGGTTCTGGTGGTGGTTCTGGTATGGGGATGCTTCGCTGGGGAGTGG

SEQ ID

NO

97
98
99
100
101
102
103
104
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TABLE 3-continued

Fluorescence protein tagged sgualene synthase construct primers
SEQ ID
NO

gene/construct

primer

sequence

YSS
YSStr
BSS
BSS

Xbal Rev
Xbal Rev
Not! Rev
Xbal Rev

GCTCTAGATCACGCTCTGTGTAAAGTGTATATA
GCTCTAGATCACTTGTACTCTTCTTCTTGTTGGGTTGG
ATAAGAATGCGGCCGCTTAGGCGCTGAGTGTGGGTCTAGG
GCTCTAGATTAGGCGCTGAGTGTGGGTCTAGG

Creating C-Terminus Squalene Synthase Constructs
Constructs to be tested in S. cerevisiae were created using
the pESC-Leu vector (Agilent) which harbors the Gall/
GallO divergent promoter to allow for galactose induction of
gene expression. Primers used to create these constructs are
listed in Table 4 (restriction sites, if any, in bold). YSS-92
was created by PCR amplifying a portion of the YSS gene
corresponding to the 92 C-terminal amino acids using the
primer sets, YSS-92 EcoRI For and YSS Natl Rev, and
YSS-92 BamHI For and YSS HindIII Rev, and cloning into
pESC-Leu with the corresponding restriction enzyme sites.
ASS-66 and YSS-64 were created in the same mamier.
ASS-YSS and YSS-ASS were created in a similar manner
using YSS-ASS-YSS or ASS-YSS-ASS as the templates for
PCR, respectively. BSS-YSS and YSS-BSS were created by
using YSS-BSS-YSS or BSS-YSS-BSS as the template for
PCR, respectively. BSS-YSS was only cloned into pESC
Leu with the EcoRI and Natl restriction sites (GallO pro
motor) due to a native BamHI restriction site in the BSSYSS coding sequence. All constructs were verified by
automated DNA sequencing.

105
106
107
108

TABLE 5
15

20

25

30

New Name

Name on tube

YSS-ASS-YSS
ASS-YSS-ASS
YSS-Ma
YSS-Mb
YSS-Mc
YSS-Md
YSS-Me
ASS-Mf
ASS-Mg
ASS-Mb
ASS-Mi
ASS-Mj

YSS-M(f)
ASS-M(f)
YSS-Md
YSS-Me
YSS-Ma
YSS-Mb
YSS-Mc
ASS-Md
ASS-Me
ASS-Ma
ASS-Mb
ASS-Mc

It will be understood that various details of the presently
disclosed subject matter can be departed from the scope of
the subject matter disclosed herein. Furthermore, the fore
going, description is for purposes of illustration only, and
not for the purpose of limitation.

TABLE 4
Primers for creating C-terminus sgualene synthase constructs
primer

sequence

YSS-92 EcoRI For
YSS-92 BamHI For
YSS-64 EcoRI For
YSS-64 BamHI For
YSS Not! Rev
YSS HindIII Rev
ASS-66 EcoRI For
ASS-66 BamHI For
ASS Not! Rev
ASS HindIII Rev
BSS-109 EcoRI For
BSS Not! Rev
BSS Hind III Rev

GGAATTCAAAACAATGAAATCTAAATTGGCTGTGCAAGATCC
CGGGATCCAAAACAATGAAATCTAAATTGGCTGTGCAAGATCC
GGAATTCAAAACAATGTACCAGGATAAATTACCTCC
CGGGATCCAAAACAATGTACCAGGATAAATTACCTCC
ATAAGAATGCGGCCGCTCACGCTCTGTGTAAAGTGTATATAT
AACCCAAGCTTTCACGCTCTGTGTAAAGTGTATATAT
GGAATTCAAAACAATGAAGACAAAGGTTGACAAGAACGATCC
CGGGATCCAAAACAATGAAGACAAAGGTTGACAAGAACGATCC
ATAAGAATGCGGCCGCTCAGTTTGCTCTGAGATATGCAAAGAC
AACCCAAGCTTTCAGTTTGCTCTGAGATATGCAAAGAC
GGAATTCAAAACAATGGAAGTCAGATGCAACACCGAGACC
ATAAGAATGCGGCCGCTTAGGCGCTGAGTGTGGGTCTAGG
AACCCAAGCTTTTAGGCGCTGAGTGTGGGTCTAGG

Saccharomyces cerevisiae Growth Inhibition Assays
Constructs were transformed into BY4741 yeast via the
lithium acetate method and plated on Yeast-Synthetic Drop
out medium plates lacking uracil. Positive transformants
were verified by PCR screening and grown in 2 mL of
Yeast-Synthetic Drop-out medium for 4 days
(OD600=9.0±0.1 after 4 days growth). Cultures were serial
diluted with water to optical densities (600 nm) equal to 0.5,
0.1, 0.02, and 0.004, and 5 µL of each dilution was spotted
on selection media containing either 2% glucose or 2%
galactose as the carbon source. Pictures were taken after 4
days growth at 28° C.

The following Table 5 provides a cross reference for this
disclosure.

SEQ ID NOS
109
110
111
112
113
114
115
116
117
118
119
120
121
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS, 161
<210> SEQ ID NO 1
<211> LENGTH, 26
<212> TYPE, PRT

<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 1
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile
1
5
10
15
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu
20
25
<210> SEQ ID NO 2
<211> LENGTH, 26
<212> TYPE, PRT

<213> ORGANISM: Schizosaccharomyces pombe

<400> SEQUENCE, 2
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile
1
5
10
15
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 26
TYPE, PRT
ORGANISM, Yarrowia lipolytica

<400> SEQUENCE, 3
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val
1
5
10
15
Leu Cys Gly Lys Ile Glu Gln His Ala Ala
20
25
<210> SEQ ID NO 4
<211> LENGTH, 29
<212> TYPE, PRT

<213> ORGANISM: Botryococcus braunii

<400> SEQUENCE, 4
Glu Val Arg Cys Asn Thr Glu Thr Ser Glu Asp Pro Ser Val Thr Thr
1
5
10
15

27
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Thr Leu Glu His Leu His Lys Ile Lys Ala Ala Cys Lys
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH, 26
TYPE, PRT
ORGANISM, Chlamydomonas reinhardtii

<400> SEQUENCE, 5

Glu Ala Lys Val Asp Pro Thr Asp Pro Ser Leu Pro Leu Thr Arg Gln
1
5
10
15
Arg Ile Ala Glu Ala Arg Lys Ala Cys Ala
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE,

Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Thr Leu Asn
1
5
10
15
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 26
TYPE, PRT
ORGANISM, Nicotiana benthamiana

<400> SEQUENCE, 7

Lys Ser Lys Val Asn Asn Asn Asp Pro Asn Ala Thr Lys Thr Leu Lys
1
5
10
15
Arg Leu Glu Val Ile Leu Lys Thr Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 26
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 8

Tyr His Arg Ile Pro Asp Ser Asn Pro Ser Ser Ser Lys Thr Arg Gln
1
5
10
15
Ile Ile Ser Thr Ile Arg Thr Gln Asn Leu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 9
LENGTH, 26
TYPE, PRT
ORGANISM, Rattus norvegicus

<400> SEQUENCE, 9

Tyr His Arg Val Pro Asn Ser Asp Pro Ser Ala Ser Lys Ala Lys Gln
1
5
10
15
Leu Ile Ser Asn Ile Arg Thr Gln Ser Leu
20
25
<210> SEQ ID NO 10
<211> LENGTH, 26
<212> TYPE, PRT

<213> ORGANISM: Saccharomyces cerevisiae

28
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-continued

<400> SEQUENCE, 10

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile
15
10
1
5
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 11
LENGTH, 26
TYPE, PRT
ORGANISM, Schizosaccharomyces pombe

<400> SEQUENCE, 11

His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile
15
10
1
5
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH, 26
TYPE, PRT
ORGANISM, Yarrowia li polytica

<400> SEQUENCE, 12

Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val
15
10
1
5
Leu Cys Gly Lys Ile Glu Gln His Ala Ala
20
25
<210> SEQ ID NO 13
<211> LENGTH, 67
<212> TYPE, PRT

<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 13
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile
1
5
10
15
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu Glu Met Tyr Gln Asp Lys
20
25
30
Leu Pro Pro Asn Val Lys Pro Asn Glu Thr Pro Ile Phe Leu Lys Val
35
40
45
Lys Glu Arg Ser Arg Tyr Asp Asp Glu Leu Val Pro Thr Gln Gln Glu
50
55
60
Glu Glu Tyr
65
<210> SEQ ID NO 14
<211> LENGTH, 67
<212> TYPE, PRT

<213> ORGANISM: Schizosaccharomyces pombe

<400> SEQUENCE, 14
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile
1
5
10
15
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu Ser Leu Phe Pro Arg Arg
20
25
30
Phe Arg Glu Met Tyr Glu Lys Ala Tyr Val Ser Lys Leu Ser Glu Gln
35
40
45
Lys Lys Gly Asn Gly Thr Gln Lys Ala Ile Leu Asn Asp Glu Gln Lys
50
55
60
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Glu Leu Tyr
65
<210>
<211>
<212>
<213>

SEQ ID NO 15
LENGTH, 67
TYPE, PRT
ORGANISM, Yarrowia lipolytica

<400> SEQUENCE, 15
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val
1
5
10
15
Leu Cys Gly Lys Ile Glu Gln His Ala Ala Leu Ile Lys Arg Gln Arg
20
25
30
Gly Pro Pro Ala Lys Thr Ile Ala Gln Leu Glu Gly Glu Arg Lys Glu
35
40
45
Met Ala Leu Ser Leu Ile Val Cys Leu Ala Val Ile Phe Ser Met Ser
50
55
60
Gly Leu Met
65
<210> SEQ ID NO 16
<211> LENGTH, 70
<212> TYPE, PRT

<213> ORGANISM: Botryococcus braunii

<400> SEQUENCE, 16
Glu Val Arg Cys Asn Thr Glu Thr Ser Glu Asp Pro Ser Val Thr Thr
1
5
10
15
Thr Leu Glu His Leu His Lys Ile Lys Ala Ala Cys Lys Ala Gly Leu
20
25
30
Ala Arg Thr Lys Asp Asp Thr Phe Asp Glu Leu Arg Ser Arg Leu Leu
35
40
45
Ala Leu Thr Gly Gly Ser Phe Tyr Leu Ala Trp Thr Tyr Asn Phe Leu
50
55
60
Asp Leu Arg Gly Pro Gly
65
70
<210>
<211>
<212>
<213>

SEQ ID NO 17
LENGTH, 34
TYPE, PRT
ORGANISM, Chlamydomonas reinhardtii

<400> SEQUENCE, 17
Glu Ala Lys Val Asp Pro Thr Asp Pro Ser Leu Pro Leu Thr Arg Gln
1
5
10
15
Arg Ile Ala Glu Ala Arg Lys Ala Cys Ala Ala Lys Leu Thr Glu Val
20
25
30
Ser Val
<210>
<211>
<212>
<213>

SEQ ID NO 18
LENGTH, 65
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 18
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Thr Leu Asn
1
5
10
15
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg Asp Ala Gly Val Leu Gln
20
25
30
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-continued

Asn Arg Lys Ser Tyr Val Asn Asp Lys Gly Gln Pro Asn Ser Val Phe
35
40
45
Ile Ile Met Val Val Ile Leu Leu Ala Ile Val Phe Ala Tyr Leu Arg
50
55
60
Ala
65
<210> SEQ ID NO 19
<211> LENGTH, 66
<212> TYPE, PRT

<213> ORGANISM: Nicotiana benthamiana
<400> SEQUENCE, 19

Lys Ser Lys Val Asn Asn Asn Asp Pro Asn Ala Thr Lys Thr Leu Lys
1
5
10
15
Arg Leu Glu Val Ile Leu Lys Thr Cys Arg Asp Ser Gly Thr Leu Asn
20
25
30
Lys Arg Lys Ser Tyr Ile Ile Arg Ser Glu Pro Asn Tyr Ser Pro Val
35
40
45
Leu Ile Val Val Ile Phe Ile Ile Leu Ala Ile Ile Leu Ala Gln Leu
50
55
60
Ser Gly
65
<210>
<211>
<212>
<213>

SEQ ID NO 20
LENGTH, 67
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 20
Tyr His Arg Ile Pro Asp Ser Asn Pro Ser Ser Ser Lys Thr Arg Gln
1
5
10
15
Ile Ile Ser Thr Ile Arg Thr Gln Asn Leu Pro Asn Cys Gln Leu Ile
20
25
30
Ser Arg Ser His Tyr Ser Pro Ile Tyr Leu Ser Phe Val Met Leu Leu
35
40
45
Ala Ala Leu Ser Trp Gln Tyr Leu Thr Thr Leu Ser Gln Val Thr Glu
50
55
60
Asp Tyr Val
65
<210> SEQ ID NO 21
<211> LENGTH, 67
<212> TYPE, PRT

<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE, 21
Tyr His Arg Val Pro Asn Ser Asp Pro Ser Ala Ser Lys Ala Lys Gln
1
5
10
15
Leu Ile Ser Asn Ile Arg Thr Gln Ser Leu Pro Asn Cys Gln Leu Ile
20
25
30
Ser Arg Ser His Tyr Ser Pro Ile Tyr Leu Ser Phe Ile Met Leu Leu
35
40
45
Ala Ala Leu Ser Trp Gln Tyr Leu Ser Thr Leu Ser Gln Val Thr Glu
50
55
60
Asp Tyr Val
65
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<210> SEQ ID NO 22
<211> LENGTH, 67
<212> TYPE, PRT

<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 22
Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile
1
5
10
15
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu Glu Met Tyr Gln Asp Lys
20
25
30
Leu Pro Pro Asn Val Lys Pro Asn Glu Thr Pro Ile Phe Leu Lys Val

35

40

45

Lys Glu Arg Ser Arg Tyr Asp Asp Glu Leu Val Pro Thr Gln Gln Glu
50
55
60
Glu Glu Tyr
65
<210> SEQ ID NO 23
<211> LENGTH, 67
<212> TYPE, PRT

<213> ORGANISM: Schizosaccharomyces pombe

<400> SEQUENCE, 23
His Tyr Lys Asn Thr Pro Lys Asp Pro Asn Phe Leu Lys Ile Ser Ile
1
5
10
15
Glu Cys Gly Lys Ile Glu Gln Val Ser Glu Ser Leu Phe Pro Arg Arg
20
25
30
Phe Arg Glu Met Tyr Glu Lys Ala Tyr Val Ser Lys Leu Ser Glu Gln
35
40
45
Lys Lys Gly Asn Gly Thr Gln Lys Ala Ile Leu Asn Asp Glu Gln Lys
50
55
60
Glu Leu Tyr
65
<210>
<211>
<212>
<213>

SEQ ID NO 24
LENGTH, 67
TYPE, PRT
ORGANISM, Yarrowia lipolytica

<400> SEQUENCE, 24
Tyr Lys Lys Ser Asp Pro Asn Asp Pro Asn Tyr Phe Arg Val Ser Val
1
5
10
15
Leu Cys Gly Lys Ile Glu Gln His Ala Ala Leu Ile Lys Arg Gln Arg
20
25
30
Gly Pro Pro Ala Lys Thr Ile Ala Gln Leu Glu Gly Glu Arg Lys Glu
35
40
45
Met Ala Leu Ser Leu Ile Val Cys Leu Ala Val Ile Phe Ser Met Ser
50
55
60
Gly Leu Met
65
<210> SEQ ID NO 25
<211> LENGTH, 26
<212> TYPE, PRT

<213> ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 25
Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Leu Asn Ile
1
5
10
15

36
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37
-continued
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 26
LENGTH, 26
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 26

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Thr Leu Asn
15
1
5
10
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 27
LENGTH, 26
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 27

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Leu Asn Ile
15
1
5
10
Gln Ile Ser Ala Val Gln Lys Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 28
LENGTH, 26
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 28

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Ala Ser Lys Thr Leu Asn
15
1
5
10
Arg Ile Ser Lys Ile Glu Gln Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 29
LENGTH, 26
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 29

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Ala Ser Lys Thr Leu Asn
10
15
1
5
Arg Leu Glu Ala Val Gln Lys Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 30
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 30

Lys Ser Lys Leu Ala Val Gln Asp Pro Asn Phe Leu Lys Thr Leu Asn
1
5
10
15
Arg Leu Glu Ala Val Gln Lys Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 31
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana
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-continued

<400> SEQUENCE, 31

Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Leu Asn Ile
1
5
10
15
Gln Ile Ser Lys Ile Glu Gln Phe Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 32
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 32

Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Ala Ser Lys Thr Leu Asn
1
5
10
15
Arg Leu Glu Lys Ile Glu Gln Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 33
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 33

Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Phe Leu Lys Leu Asn Ile
1
5
10
15
Gln Leu Glu Ala Val Gln Lys Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 34
LENGTH, 26
TYPE, PRT
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 34

Lys Thr Lys Val Asp Lys Asn Asp Pro Asn Phe Leu Lys Leu Asn Ile
1
5
10
15
Gln Ile Ser Lys Ile Glu Gln Leu Cys Arg
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 35
LENGTH, 4
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 35

Lys Ile Glu Gln
1
<210>
<211>
<212>
<213>

SEQ ID NO 36
LENGTH, 7
TYPE, PRT
ORGANISM, Saccharomyces cerevisiae

<400> SEQUENCE, 36

Phe Leu Lys Leu Asn Ile Gln
1
5
<210>
<211>
<212>
<213>
<220>

SEQ ID NO 37
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FE ATURE,

41
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-continued
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (9)
<400> SEQUENCE, 37

aggcgcgcca aaacaatggg aaagctatta caatggc
<210>
<211>
<212>
<213>
<220>
<223>

37

SEQ ID NO 38
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 38

cgcggatcca aaacaatggg aaagctatta caatggc

<210>
<211>
<212>
<213>
<220>
<223>

37

SEQ ID NO 39
LENGTH, 32
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 39

gctctagatc acgctctgtg taaagtgtat at
<210>
<211>
<212>
<213>
<220>
<223>

32

SEQ ID NO 40
LENGTH, 35
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 40

ataagaatgc ggccgctcac gctctgtgta aagtg
<210>
<211>
<212>
<213>
<220>
<223>

35

SEQ ID NO 41
LENGTH, 26
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 41

gctctagatc acttgtactc ttcttc

<210>
<211>
<212>
<213>

SEQ ID NO 42
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence

26

43
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<220> FEATURE,
<223> OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 42

gggctcgagt cacttgtact cttcttc
<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 43
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from S. cerevisiae cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 43

ataagaatgc ggccgctcac ttgtactctt cttcttg

37

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 44
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from B. braunii cloned into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)

<400> SEQUENCE, 44
ccggaattca aaacaatggg gatgcttcgc tggggagtgg

40

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 45
LENGTH, 35
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from B. braunii cloned into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (6) .. (11)

<400> SEQUENCE, 45
atcccaagct tttaggcgct gagtgtgggt ctagg

35

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 46
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from B. braunii cloned into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 46
ataagaatgc ggccgcttag gcgctgagtg tgggtctagg
<210> SEQ ID NO 47
<211> LENGTH, 38
<212> TYPE, DNA

40

45

US 9,821,037 Bl

46

-continued
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Squalene synthases from R. norvegicus cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 47

ggaattcaaa acaatggagt tcgtgaagtg tctaggcc
<210>
<211>
<212>
<213>
<220>
<223>

38

SEQ ID NO 48
LENGTH, 30
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from R. norvegicus cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 48

cgcggatcca tggaccggaa ctcgctcagc
<210>
<211>
<212>
<213>
<220>
<223>

30

SEQ ID NO 49
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from R. norvegicus cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 49

ataagaatgc ggccgctcag tgttctctct ggacatagtc
<210>
<211>
<212>
<213>
<220>
<223>

40

SEQ ID NO 50
LENGTH, 34
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from R. norvegicus cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 50

ccgctcgagt cagctctgcg tcctgatgtt ggag
<210>
<211>
<212>
<213>
<220>
<223>

34

SEQ ID NO 51
LENGTH, 29
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from N. benthamiana cloned
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 51

ggaattcatg gggagtttga gggctattc
<210> SEQ ID NO 52
<211> LENGTH, 30

29
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<213>
<220>
<223>

48
-continued

TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from N. benthamiana clone d
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 52

gctctagact aagatcggtt tccggatagc
<210>
<211>
<212>
<213>
<220>
<223>

30

SEQ ID NO 53
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from N. benthamiana clone d
into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 53

ataagaatgc ggccgcctaa gatcggtttc cggatagc

38

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 54
LENGTH, 39
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from A. thaliana clone d into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (9)
<400> SEQUENCE, 54
ccggaattca aaacaatggg gagcttgggg acgatgctg

39

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 55
LENGTH, 29
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from A. thaliana clone d into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 55
gctctagatc agtttgctct gagatatgc

29

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 56
LENGTH, 41
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Squalene synthases from A. thaliana clone d into
the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 56
ataagaatgc ggccgctcag tttgctctga gatatgcaaa g
<210> SEQ ID NO 57

41
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<211>
<212>
<213>
<220>
<223>

LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Reverse primer is designed to pair with the
Squalene synthases B. braunii EcoRI

<220> FEATURE,
<221> NAME/KEY, mutation
<222> LOCATION, ( 6) .. (11)
<400> SEQUENCE, 57

atcccaagct tctctgctaa tttgagg
<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 58
LENGTH, 29
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer is designed to pair with the Squalene
synthases S. cerevisiae

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (5) .. (10)
<400> SEQUENCE, 58

atccaagctt aaatctaaat tggctgtgc

29

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 59
LENGTH, 50
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer is designed to pair with primer squalene
synthases B. braunii EcoRI to amplify a fragment of the BSS-YSS

<220>
<221>
<222>
<220>
<221>
<222>

FEATURE,
NAME/KEY,
LOCATION,
FEATURE,
NAME/KEY,
LOCATION,

construct with NgoMIV and NotI restriction sites
misc_binding

(10) .. (17)

misc_binding

(22) .. (27)

<400> SEQUENCE, 59
ataaagaatg cggccgcgaa tgccggcttc cataaactgt tcgatcttgg

50

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 60
LENGTH, 39
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer is designed to pair with primer squalene
synthases B. braunii NotI Rev
<220> FEATURE,
<221> NAME/KEY, mutation
<222> LOCATION, (10) .. (15)
<400> SEQUENCE, 60
gcaaagaatg ccggcctggc acgcacaaaa gatgacacc

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 61
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,

<223> OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and B. braunii

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (49)
<400> SEQUENCE, 61

39
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cttacgtgat atcgaagtca gatgcaacac cgagaccagc gaggatccc

49

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 62
LENGTH, 51
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and B. braunii
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (51)
<400> SEQUENCE, 62

gcatctgact tcgatatcac gtaagtaata gtcaaaaatc tcgacacagc c

51

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 63
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and A. thaliana
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (48)
<400> SEQUENCE, 63
cttacgtgat atcaagacaa aggttgacaa gaacgatcca aatgccag

48

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 64
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and A. thaliana
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (48)
<400> SEQUENCE, 64

caacctttgt cttgatatca cgtaagtaat agtcaaaaat ctcgacac

48

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 65
LENGTH, 47
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of A. thaliana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (47)
<400> SEQUENCE, 65

cctgcatgct gaaatctaaa ttggctgtgc aagatccaaa tttctta
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 66
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of A. thaliana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (48)

47
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<400> SEQUENCE, 66
gccaatttag atttcagcat gcaggaaaaa tcatagaaag caccatag

48

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 67
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and N. benthamiana
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (48)

<400> SEQUENCE, 67
cttacgtgat atcaaatcca aggttaataa taatgatcca aatgcaac

48

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 68
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae and N. benthamiana
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (49)

<400> SEQUENCE, 68
ttaaccttgg atttgatatc acgtaagtaa tagtcaaaaa tctcgacac

49

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 69
LENGTH, 53
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of N. benthamiana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (53)
<400> SEQUENCE, 69

gacttttctt gtatgctgaa atctaaattg gctgtgcaag atccaaattt ctt

53

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 70
LENGTH, 53
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of N. benthamiana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (53)
<400> SEQUENCE, 70

gccaatttag atttcagcat acaagaaaag tcaaaaaaag caccatatac ate
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 71
LENGTH, 54
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae, B. braunii and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (54)

53
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<400> SEQUENCE, 71
caaagctgcc tgcaaggaaa tgtaccagga taaattacct cctaacgtga agcc

54

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 72
LENG TH, 51
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae, B. braunii and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (51)
<400> SEQUENCE, 72

cctggtacat ttccttgcag gcagctttga tcttatgcag gtgttccaga g

51

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 73
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae, A. thaliana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)

<400> SEQUENCE, 73
aagacaaagg ttgacaagaa cgatccaaat gccagtaaga cactaaaccg acttgaagcc

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 74
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of S. cerevisiae, A. thaliana and S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)

<400> SEQUENCE, 74
tctgcagagt ttctgaacgg cttcaagtcg gtttagtgtc ttactggcat ttggatcgtt

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 75
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of A. thaliana, S. cerevisiae and A. thaliana
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)

<400> SEQUENCE, 75
aaatctaaat tggctgtgca agatccaaat ttcttaaaat tgaacattca aatctccaag
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 76
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Construction of chimeric squalene synthase
primer sequence of A. thaliana, S. cerevisiae and A. thaliana
<220> FEATURE,
<221> NAME/KEY, misc_binding

60

57
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<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 76
ttccataaac tgttcgatct tggagatttg aatgttcaat tttaagaaat ttggatcttg

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 77
LENGTH, 48
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (48)
<400> SEQUENCE, 77
ctccgccgtt caaaagttta tggaagaaat gtaccaggat aaattacc

48

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 78
LENGTH, 44
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (44)
<400> SEQUENCE, 78
ccataaactt ttgaacggcg gagatttgaa tgttcaattt taag

44

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 79
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (49)
<400> SEQUENCE, 79
aatgccagta agacactaaa ccgtatctcc aagatcgaac agtttatgg

49

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 80
LENGTH, 50
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (50)
<400> SEQUENCE, 80
gatacggttt agtgtcttac tggcatttgg atcttgcaca gccaatttag
<210>
<211>
<212>
<213>
<220>
<223>

50

SEQ ID NO 81
LENGTH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
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<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 81
gccagtaaga cactaaaccg tcttgaagcc gttcagaagt ttatggaaga aatgtaccag

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 82
LENGTH, 58
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (58)
<400> SEQUENCE, 82
cttctgaacg gcttcaagac ggtttagtgt cttactggca tttggatctt gcacagcc

58

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 83
LENGTH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 83
aagacaaagg ttgacaagaa cgatccaaat gccagtaagt tgaacattca aatctccaag

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 84
LENGTH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 84
cttactggca tttggatcgt tcttgtcaac ctttgtcttg atatcacgta agtaatagtc

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 85
LENGTH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 85
acactaaacc gacttgaagc cgttcagaaa ctctgcagag aaatgtacca ggataaatta
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 86
LENGTH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Constructs of S. cerevisiae squalene synthase
cloned into the Yep352 vector

60
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<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 86
tctgcagagt ttctgaacgg cttcaagtcg gtttagtgtt tttaagaaat ttggatcttg
<210>
<211>
<212>
<213>
<220>
<223>

60

SEQ ID NO 87
LENGTH, 43
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (43)
<400> SEQUENCE, 87

cttgaaaaga tcgaacagct ctgcagagac gctggagttc ttc
<210>
<211>
<212>
<213>
<220>
<223>

43

SEQ ID NO 88
LENGTH, 44
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (44)
<400> SEQUENCE, 88

cagagctgtt cgatcttttc aagtcggttt agtgtcttac tggc
<210>
<211>
<212>
<213>
<220>
<223>

44

SEQ ID NO 89
LENGTH, 50
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (50)
<400> SEQUENCE, 89

aatttcttaa aattgaacat tcaacttgaa gccgttcaga aactctgcag

<210>
<211>
<212>
<213>
<220>
<223>

50

SEQ ID NO 90
LENGTH, 50
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (50)
<400> SEQUENCE, 90

aagttgaatg ttcaatttta agaaatttgg atcgttcttg tcaacctttg
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 91
LENGTH, 58
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase

50
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cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (58)
<400> SEQUENCE, 91

ttcttaaaat tgaacattca aatctccaag atcgaacagc tctgcagaga cgctggag

<210>
<211>
<212>
<213>
<220>
<223>

58

SEQ ID NO 92
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 92

ctgttcgatc ttggagattt gaatgttcaa ttttaagaaa tttggatcgt tcttgtcaac
<210>
<211>
<212>
<213>
<220>
<223>

60

SEQ ID NO 93
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 93

aaatctaaat tggctgtgca agatccaaat ttcttaaaaa cactaaaccg acttgaagcc

<210>
<211>
<212>
<213>
<220>
<223>

60

SEQ ID NO 94
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 94

ttttaagaaa tttggatctt gcacagccaa tttagatttc agcatgcagg aaaaatcata
<210>
<211>
<212>
<213>
<220>
<223>

60

SEQ ID NO 95
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 95

ttgaacattc aaatctccaa gatcgaacag tttatggaag acgctggagt tcttcaaaac

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 96
LENG TH, 60
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,

60
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<223> OTHER INFORMATION, Constructs of A. thaliana squalene synthase
cloned into the Yep352 vector

<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (60)
<400> SEQUENCE, 96

ttccataaac tgttcgatct tggagatttg aatgttcaac ttactggcat ttggatcgtt

60

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 97
LENGTH, 39
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (9)
<400> SEQUENCE, 97
aggcgcgcca aaacaatgtc taaaggtgaa gaattattc

39

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 98
LENGTH, 39
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 98
ccgctcgaga aaacaatggt gcgctcctcc aagaacgtc

39

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 99
LENGTH, 39
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (9)

<400> SEQUENCE, 99
aggcgcgcca aaacaatggt gcgctcctcc aagaacgtc

39

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 100
LENGTH, 52
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (52)
<400> SEQUENCE, 100
cataccagaa ccaccaccag aaccaccttt gtacaattca tccataccat gg

<210>
<211>
<212>
<213>

SEQ ID NO 101
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence

52
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<220> FEATURE,
<223> OTHER INFORMATION, Fluorescence pr otein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (49)
<400> SEQUENCE, 101
cataccagaa ccaccaccag aaccacccag gaacaggtgg tggcggccc

49

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 102
LENGTH, 51
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence pr otein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (51)

<400> SEQUENCE, 102
caaaggtggt tctggtggtg gttctggtat gggaaagcta ttacaattgg c

51

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 103
LENGTH, 53
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence pr otein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (53)
<400> SEQUENCE, 103
caaaggtggt tctggtggtg gttctggtat ggggatgctt cgctggggag tgg

53

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 104
LENGTH, 53
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence pr otein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (53)

<400> SEQUENCE, 104
cctgggtggt tctggtggtg gttctggtat ggggatgctt cgctggggag tgg

53

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 105
LENGTH, 33
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence pr otein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)

<400> SEQUENCE, 105
gctctagatc acgctctgtg taaagtgtat ata
<210> SEQ ID NO 106
<211> LENGTH, 38
<212> TYPE, DNA

33
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<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 106
gctctagatc acttgtactc ttcttcttgt tgggttgg

38

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 107
LENG TH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (9) .. (16)
<400> SEQUENCE, 107

ataagaatgc ggccgcttag gcgctgagtg tgggtctagg

40

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 108
LENG TH, 32
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged squalene synthase
construct primer
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 108

gctctagatt aggcgctgag tgtgggtcta gg
<210>
<211>
<212>
<213>
<220>

32

SEQ ID NO 109
LENG TH, 42
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,

<223> OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae

<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (2) .. (7)

<400> SEQUENCE, 109
ggaattcaaa acaatgaaat ctaaattggc tgtgcaagat cc

<210>
<211>
<212>
<213>
<220>

42

SEQ ID NO 110
LENG TH, 43
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,

<223> OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae

<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (3) .. (8)

<400> SEQUENCE, 110
cgggatccaa aacaatgaaa tctaaattgg ctgtgcaaga tee

<210> SEQ ID NO 111
<211> LENG TH, 36

43

US 9,821,037 Bl
71

72
-continued

<212>
<213>
<220>
<223>

TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 111

ggaattcaaa acaatgtacc aggataaatt acctcc

36

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 112
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (3) .. (7)
<400> SEQUENCE, 112
cgggatccaa aacaatgtac caggataaat tacctcc

37

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 113
LENGTH, 42
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, ( 9) .. (16)
<400> SEQUENCE, 113
ataagaatgc ggccgctcac gctctgtgta aagtgtatat at

42

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 114
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for S. cerevisiae
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (6) .. (11)
<400> SEQUENCE, 114
aacccaagct ttcacgctct gtgtaaagtg tatatat

37

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 115
LENGTH, 42
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for A. thaliana
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (2) .. (7)
<400> SEQUENCE, 115
ggaattcaaa acaatgaaga caaaggttga caagaacgat cc
<210> SEQ ID NO 116

42
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<211>
<212>
<213>
<220>
<223>

LENGTH, 43
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for A. thaliana
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (3) .. (8)
<400> SEQUENCE, 116

cgggatccaa aacaatgaag acaaaggttg acaagaacga tee

43

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 117
LENGTH, 43
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for A. thaliana
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, ( 9) .. (16)
<400> SEQUENCE, 117
ataagaatgc ggccgctcag tttgctctga gatatgcaaa gac

43

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 118
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for A. thaliana
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (6) .. (11)

<400> SEQUENCE, 118
aacccaagct ttcagtttgc tctgagatat gcaaagac

38

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 119
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for B. braunii
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, (2) .. (7)

<400> SEQUENCE, 119
ggaattcaaa acaatggaag tcagatgcaa caccgagacc

40

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 120
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for B. braunii
<220> FEATURE,
<221> NAME/KEY, C_region
<222> LOCATION, ( 9) .. (16)

<400> SEQUENCE, 120
ataagaatgc ggccgcttag gcgctgagtg tgggtctagg

40
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US 9,821,037 Bl

76

-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 121
LENGTH, 35
TYPE, DNA
ORGANISM, A rtificial Sequence
FEATURE,
OTHER INFORMATION: Primer for creating C-terminus squalene
synthase construct for B. braunii
<220> FEATURE,
<221> NAM E/KEY, C_region
<222> LO CATION, (6) .. (11)
<400> SEQUENCE, 121
aacccaagct tttaggcgct gagtgtgggt ctagg
<210>
<211>
<212>
<213>

35

SEQ ID NO 122
LENGTH, 1335
TYPE, DNA
ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 122
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>

SEQ ID NO 123
LENGTH, 1263
TYPE, DNA
ORGANISM: Saccharomyces cerevisiae

<400> SEQUENCE, 123
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60
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aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttcacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcgat

960

gtaaagattc gtaagggtac tacctgctgt ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

tga

1263

<210>
<211>
<212>
<213>

SEQ ID NO 124
LENGTH, 1386
TYPE, DNA
ORGANISM, Botryococcus braunii

<400> SEQUENCE, 124

atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc

60

ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc

120

ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc

180

cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca

240

gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat

300

gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg

360

ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa

420

gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag

480

ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg

540

ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc

600

agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac

660

tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg

720

ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg

780

tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac

840

atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc

900

us 9,821,037 Bl

80

79
-continued
ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct

960

gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg

1020

atgtaccgtc atttcctcaa cttcgcagag aagctggaag tcagatgcaa caccgagacc

1080

agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc

1140

aaggctgggc tggcacgcac aaaagatgac acctttgacg aattgaggag caggttgtta

1200

gcgctgacgg gaggcagctt ctacctcgcc tggacctaca atttcctaga ccttcgaggc

1260

ccgggagacc tgcccacctt cttatctgta acccaacatt ggtggtctat tctgatcttc

1320

ctcatttcga ttgccgtctt ctttattccg tcgaggccct cacctagacc cacactcagc

1380

gcctaa

1386

<210> SEQ ID NO 125
<211> LENGTH, 1251
<212> TYPE, DNA
<213> ORGANISM, Rattus rattus
<400> SEQUENCE, 125

atggagttcg tgaagtgtct aggccacccg gaggagttct acaacctgct gcgattccgc

60

atgggaggcc ggcggaattt catacccaag atggaccgga actcgctcag caacagcttg

120

aagacttgct ataagtatct tgatcagacc agtcgcagct tcgccgcggt tatccaggcg

180

ctggatgggg acatacgtca tgcggtgtgt gtgttttacc tgatcctccg agccatggac

240

acagtggagg atgacatggc catcagtgtg gagaagaaga tcccactgct gcgaaacttt

300

cacactttcc tctatgagcc ggagtggcgg ttcaccgaga gcaaggagaa gcaccgagta

360

gtgctggagg acttccccac gatctccctg gagtttagaa atttggctga gaaatatcaa

420

acagtgatcg ctgacatctg tcacaggatg ggatgtggga tggcagaatt tctaaacaag

480

gatgtaacct ccaaacagga ctgggacaag tactgtcact atgttgctgg actggtggga

540

atcggccttt ctcgcctatt ctctgcctca gagtttgaag atcccatagt tggtgaagac

600

acagagtgtg ccaattctat gggtctgttt ctgcagaaaa caaatatcat tcgtgattat

660

ctggaagacc aacaagaagg aagacagttt tggcctcaag aggtatgggg caaatatgtt

720

aagaagctgg aagactttgt taagccagag aacgtagatg tggccgtgaa gtgcttgaat

780

gaactcataa ccaacgccct acaacacatc cctgacgtca tcacctacct gtcaaggctc

840

cggaaccaaa gtgtgtttaa cttctgtgcc attccacagg taatggccat tgctacgctg

900

gctgcctgtt acaataacca tcaggtattc aagggagtag tgaagattcg gaaggggcaa

960

gcagttaccc tcatgatgga tgccaccaac atgccagctg tcaaagctat catataccag

1020

tacatagaag agatttatca ccgggtcccc aactcagacc cgtcagctag caaggccaag

1080

cagctcatct ccaacatcag gacgcagagc cttcccaatt gccagctcat ctcccgaagc

1140

cactactccc ccatttacct gtccttcatc atgctcttgg ctgccctgag ctggcagtac

1200

ttgagcactc tgtcccaggt cacagaagac tatgtccaga gagaacactg a

1251

<210>
<211>
<212>
<213>

SEQ ID NO 126
LENGTH, 1236
TYPE, DNA
ORGANISM, Nicotiana tabacum

<400> SEQUENCE, 126

atggggagtt tgagggctat tctgaagaat ccagaggatt tatatccatt ggtgaagctg

60

81
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aagctagcgg ctcgacacgc ggagaagcag atcccgccgt ctccaaattg gggcttctgt

120

tactcaatgc ttcataaggt ttctcgtagc tttgctctcg tcattcaaca acttccagtc

180

gagcttcgtg acgccgtgtg cattttctat ttggttcttc gagcacttga cactgttgag

240

gatgatacca gcattcccac cgatgttaaa gttcctattc tgatctcttt tcatcagcat

300

gtttatgatc gcgaatggca tttttcatgt ggtacaaagg agtacaaggt tctcatggac

360

cagttccatc atgtatcaac tgcttttctg gagcttagga aacattatca gcaggcaatt

420

gaggatatta ccatgaggat gggtgcagga atggcaaaat tcatatgcaa ggaggtggaa

480

acaaccgatg attatgacga atattgtcac tatgtagctg ggcttgttgg gctaggattg

540

tcaaaactgt tccatgcctc tgagaaagaa gatctggctt cagattctct ctccaactcc

600

atgggtttat ttcttcagaa aacaaacatc attagagatt atttggaaga cataaatgaa

660

gtacccaagt gccgtatgtt ctggccccgt gaaatatgga gtaaatatgt taacaagctt

720

gaggaattaa agtacgagga taactcggcc aaagcagtgc aatgtctaaa tgacatggtc

780

actaatgctt tatcacatgt agaagattgt ttgacttaca tgtctgcttt gcgtgatcct

840

tccatctttc gattctgtgc tattccacag gtcatggcaa ttgggacatt agctatgtgc

900

tacgacaaca ttgaagtctt cagaggagtg gtaaaaatga gacgtggtct gactgctaag

960

gtcattgacc ggaccaggac tattgcagat gtatatggtg ctttttttga cttttcttgt

1020

atgctgaaat ccaaggttaa taataatgat ccaaatgcaa caaaaactct gaagaggctc

1080

gaagtgatcc tgaaaacttg cagagattcg ggaaccttga acaaaaggaa atcctacata

1140

atcaggagcg agcctaatta cagtccagtt ctgattgttg tcattttcat catactggct

1200

attattctcg cacagctatc cggaaaccga tcttag

1236

<210>
<211>
<212>
<213>

SEQ ID NO 127
LENGTH, 1233
TYPE, DNA
ORGANISM, Arabidopsis thaliana

<400> SEQUENCE, 127

atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960
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gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gacactaaac

1080

cgacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 128
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase gene consisting of
1,104 bp of the Botryococcus braunii squalene synthase encoding
for the amino terminal 368 amino acids and 228 bp of the yeast
gene encoding for 76 amino acids of the carboxy terminal domain
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1335)

<400> SEQUENCE, 128
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc

60

ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc

120

ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc

180

cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca

240

gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat

300

gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg

360

ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa

420

gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag

480

ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg

540

ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc

600

agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac

660

tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg

720

ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg

780

tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac

840

atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc

900

ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct

960

gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg

1020

atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catctcgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 129
LENGTH, 1263
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
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<223> OTHER INFORMATION, Chimeric squalene synthase gene consisting of
1,104 bp of the Botryococcus braunii squalene synthase, followed
by 155 bp of the carboxy terminal domain of the yeast squalene
synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1263)
<400> SEQUENCE, 129
atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc

60

ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc

120

ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc

180

cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca

240

gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat

300

gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg

360

ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa

420

gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag

480

ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg

540

ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc

600

agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac

660

tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg

720

ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg

780

tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac

840

atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc

900

ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct

960

gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg

1020

atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

tga

1263

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 130
LENGTH, 1386
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of first
1,056 bp of the yeast squalene synthase gene coding for the first
352 amino acids, followed by 330 bp coding for the carboxy
terminal 110 amino acids of the Botryococcus braunii squalene
synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1386)

<400> SEQUENCE, 130

atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240
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atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcgaag tcagatgcaa caccgagacc

1080

agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc

1140

aaggctgggc tggcacgcac aaaagatgac acctttgacg aattgaggag caggttgtta

1200

gcgctgacgg gaggcagctt ctacctcgcc tggacctaca atttcctaga ccttcgaggc

1260

ccgggagacc tgcccacctt cttatctgta acccaacatt ggtggtctat tctgatcttc

1320

ctcatttcga ttgccgtctt ctttattccg tcgaggccct cacctagacc cacactcagc

1380

gcctaa

1386

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 131
LENGTH, 1257
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of first
1,056 bp of the yeast squalene synthase gene coding for the first
352 amino acids, followed by 201 bp coding for the carboxy
terminal 67 amino acids of the Arabidopsis thaliana squalene
synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1257)

<400> SEQUENCE, 131
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660
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accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat

1080

ccaaatgcca gtaagacact aaaccgactt gaagccgttc agaaactctg cagagacgct

1140

ggagttcttc aaaacagaaa atcttatgtt aatgacaaag gacaaccaaa cagtgtcttt

1200

attataatgg ttgtgattct actggccata gtctttgcat atctcagagc aaactga

1257

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 132
LENGTH, 1311
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of first
1,032 bp of the Arabidopsis squalene synthase gene coding for the
first 344 amino acids, followed by 276 bp coding for the carboxy
terminal 92 amino acids of the yeast squalene synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1311)

<400> SEQUENCE, 132
atggggagct tggggacgat gctgagatat ccggatgaca tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct gcagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa attgaacatt

1080

caaatctcca agatcgaaca gtttatggaa gaaatgtacc aggataaatt acctcctaac

1140

gtgaagccaa atgaaactcc aattttcttg aaagttaaag aaagatccag atacgatgat

1200

gaattggttc caacccaaca agaagaagag tacaagttca atatggtttt atctatcatc

1260

ttgtccgttc ttcttgggtt ttattatata tacactttac acagagcgtg a

1311
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<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 133
LENGTH, 1266
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of 1,062
bp of the yeast squalene synthase gene coding for the first 354
amino acids, followed by 201 bp coding for the carboxy terminal 67
amino acids of the tobacco squalene synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1266)
<400> SEQUENCE, 133

atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ccaaggttaa taataatgat

1080

ccaaatgcaa caaaaactct gaagaggctc gaagtgatcc tgaaaacttg cagagattcg

1140

ggaaccttga acaaaaggaa atcctacata atcaggagcg agcctaatta cagtccagtt

1200

ctgattgttg tcattttcat catactggct attattctcg cacagctatc cggaaaccga

1260

tcttag

1266

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 134
LENGTH, 1305
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of 1,029
bp of the tobacco squalene synthase gene coding for the first 343
amino acids, followed by 273 bp coding for the carboxy terminal 91
amino acids of the yeast squalene synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1305)
<400> SEQUENCE, 134

atggggagtt tgagggctat tctgaagaat ccagaggatt tatatccatt ggtgaagctg

60
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aagctagcgg ctcgacacgc ggagaagcag atcccgccgt ctccaaattg gggcttctgt

120

tactcaatgc ttcataaggt ttctcgtagc tttgctctcg tcattcaaca acttccagtc

180

gagcttcgtg acgccgtgtg cattttctat ttggttcttc gagcacttga cactgttgag

240

gatgatacca gcattcccac cgatgttaaa gttcctattc tgatctcttt tcatcagcat

300

gtttatgatc gcgaatggca tttttcatgt ggtacaaagg agtacaaggt tctcatggac

360

cagttccatc atgtatcaac tgcttttctg gagcttagga aacattatca gcaggcaatt

420

gaggatatta ccatgaggat gggtgcagga atggcaaaat tcatatgcaa ggaggtggaa

480

acaaccgatg attatgacga atattgtcac tatgtagctg ggcttgttgg gctaggattg

540

tcaaaactgt tccatgcctc tgagaaagaa gatctggctt cagattctct ctccaactcc

600

atgggtttat ttcttcagaa aacaaacatc attagagatt atttggaaga cataaatgaa

660

gtacccaagt gccgtatgtt ctggccccgt gaaatatgga gtaaatatgt taacaagctt

720

gaggaattaa agtacgagga taactcggcc aaagcagtgc aatgtctaaa tgacatggtc

780

actaatgctt tatcacatgt agaagattgt ttgacttaca tgtctgcttt gcgtgatcct

840

tccatctttc gattctgtgc tattccacag gtcatggcaa ttgggacatt agctatgtgc

900

tacgacaaca ttgaagtctt cagaggagtg gtaaaaatga gacgtggtct gactgctaag

960

gtcattgacc ggaccaggac tattgcagat gtatatggtg ctttttttga cttttcttgt

1020

atgctgaaat ctaaattggc tgtgcaagat ccaaatttct taaaattgaa cattcaaatc

1080

tccaagatcg aacagtttat ggaagaaatg taccaggata aattacctcc taacgtgaag

1140

ccaaatgaaa ctccaatttt cttgaaagtt aaagaaagat ccagatacga tgatgaattg

1200

gttccaaccc aacaagaaga agagtacaag ttcaatatgg ttttatctat catcttgtcc

1260

gttcttcttg ggttttatta tatatacact ttacacagag cgtga

1305

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 135
LENGTH, 1377
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056
bp of the B. braunii squalene synthase gene coding for the first
352 amino acids, followed by 84 bp encoding for 28 amino acids of
a linker domain of the yeast squalene synthase, then 234 bp of
the B.
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1377)
<400> SEQUENCE, 135

atggggatgc ttcgctgggg agtggagtct ttgcagaatc cagatgaatt aatcccggtc

60

ttgaggatga tttatgctga taagtttgga aagatcaagc caaaggacga agaccggggc

120

ttctgctatg aaattttaaa ccttgtttca agaagttttg caatcgtcat ccaacagctc

180

cctgcacagc tgagggaccc agtctgcata ttttaccttg tactacgcgc cctggacaca

240

gtcgaagatg atatgaaaat tgcagcaacc accaagattc ccttgctgcg tgacttttat

300

gagaaaattt ctgacaggtc attccgcatg acggccggag atcaaaaaga ctacatcagg

360

ctgttggatc agtaccccaa agtgacaagc gttttcttga aattgacccc ccgtgaacaa

420

gagataattg cagacattac aaagcggatg gggaatggaa tggctgactt cgtgcataag

480

ggtgttcccg acacagtggg ggactacgac ctttactgcc actatgttgc tggggtggtg

540

ggtctcgggc tttcccagtt gttcgttgcg agtggactac agtcaccctc tttgacccgc

600
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agtgaagacc tttccaatca catgggcctc ttccttcaga agaccaacat catccgcgac

660

tactttgagg acatcaatga gctgcctgcc ccccggatgt tctggcccag agagatctgg

720

ggcaagtatg cgaacaacct cgctgagttc aaagacccgg ccaacaaggc ggctgcaatg

780

tgctgcctca acgagatggt cacagatgca ttgaggcacg cggtgtactg cctgcagtac

840

atgtccatga ttgaggatcc gcagatcttc aacttctgtg ccatccctca gaccatggcc

900

ttcggcaccc tgtctttgtg ttacaacaac tacactatct tcacagggcc caaagcggct

960

gtgaagctgc gtaggggcac cactgccaag ctgatgtaca cctctaacaa tatgtttgcg

1020

atgtaccgtc atttcctcaa cttcgcagag aagcttaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccaagatcg aacagtttat ggaagccggc

1140

ctggcacgca caaaagatga cacctttgac gaattgagga gcaggttgtt agcgctgacg

1200

ggaggcagct tctacctcgc ctggacctac aatttcctag accttcgagg cccgggagac

1260

ctgcccacct tcttatctgt aacccaacat tggtggtcta ttctgatctt cctcatttcg

1320

attgccgtct tctttattcc gtcgaggccc tcacctagac ccacactcag cgcctaa

1377

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 136
LENGTH, 1344
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056
bp of the yeast squalene synthase gene coding for the first 352
amino acids, followed by 87 bp encoding for 29 amino acids of a
linker domain of the B. braunii squalene synthase, then 201 bp of
the yeast
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1344)

<400> SEQUENCE, 136
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcgaag tcagatgcaa caccgagacc

1080
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agcgaggatc ccagcgtgac caccactctg gaacacctgc ataagatcaa agctgcctgc

1140

aaggaaatgt accaggataa attacctcct aacgtgaagc caaatgaaac tccaattttc

1200

ttgaaagtta aagaaagatc cagatacgat gatgaattgg ttccaaccca acaagaagaa

1260

gagtacaagt tcaatatggt tttatctatc atcttgtccg ttcttcttgg gttttattat

1320

atatacactt tacacagagc gtga

1344

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 137
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Chimeric squalene synthase consisting of 1,056
bp of the y east squalene synthase gene coding for the first 352
amino acids, followed by 78 bp encoding for 26 amino acids of a
linker domain of the Arabidopsis squalene synthase, then 201 bp of
the yeast
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1335)
<400> SEQUENCE, 137

atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat

1080

ccaaatgcca gtaagacact aaaccgactt gaagccgttc agaaactctg cagagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 138
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
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<223> OTHER INFORMATION, Chimeric squalene synthase consisting of 1,032
bp of the Arabidopsis squalene synthase gene coding for the first
344 amino acids, followed by 78 bp encoding for 26 amino acids of
a linker do main of the yeast squalene synthase, then 120 bp of the
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1) .. (1233)
<400> SEQUENCE, 138
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa attgaacatt

1080

caaatctcca agatcgaaca gtttatggaa gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 139
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: S. cerevisiae squalene synthase constructs
cloned into YEp352
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1057) .. (1095)
<400> SEQUENCE, 139
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

101
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caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaga caaaggttga caagaacgat

1080

ccaaatgcca gtaagttgaa cattcaaatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 140
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: S. cerevisiae squalene synthase constructs
cloned into YEp353
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1096) .. (1134)

<400> SEQUENCE, 140
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960
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gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaaacact aaaccgactt gaagccgttc agaaactctg cagagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 141
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: S. cerevisiae squalene synthase constructs
cloned into YEp354
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1114) .. (1125)
<400> SEQUENCE, 141
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatttct taaaattgaa cattcaaatc tccgccgttc aaaagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>

SEQ ID NO 142
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
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<220> FEATURE,
<223> OTHER INFORMATION: S. cerevisiae squalene synthase constructs
cloned into YEp355
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1087) .. (1107)
<400> SEQUENCE, 142
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300

gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatgcca gtaagacact aaaccgtatc tccaagatcg aacagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 143
LENGTH, 1335
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: S. cerevisiae squalene synthase constructs
cloned into YEp356
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1087) .. (1125)

<400> SEQUENCE, 143
atgggaaagc tattacaatt ggcattgcat ccggtcgaga tgaaggcagc tttgaagctg

60

aagttttgca gaacaccgct attctccatc tatgatcagt ccacgtctcc atatctcttg

120

cactgtttcg aactgttgaa cttgacctcc agatcgtttg ctgctgtgat cagagagctg

180

catccagaat tgagaaactg tgttactctc ttttatttga ttttaagggc tttggatacc

240

atcgaagacg atatgtccat cgaacacgat ttgaaaattg acttgttgcg tcacttccac

300
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gagaaattgt tgttaactaa atggagtttc gacggaaatg cccccgatgt gaaggacaga

360

gccgttttga cagatttcga atcgattctt attgaattcc acaaattgaa accagaatat

420

caagaagtca tcaaggagat caccgagaaa atgggtaatg gtatggccga ctacatctta

480

gatgaaaatt acaacttgaa tgggttgcaa accgtccacg actacgacgt gtactgtcac

540

tacgtagctg gtttggtcgg tgatggtttg acccgtttga ttgtcattgc caagtttgcc

600

aacgaatctt tgtattctaa tgagcaattg tatgaaagca tgggtctttt cctacaaaaa

660

accaacatca tcagagatta caatgaagat ttggtcgatg gtagatcctt ctggcccaag

720

gaaatctggt cacaatacgc tcctcagttg aaggacttca tgaaacctga aaacgaacaa

780

ctggggttgg actgtataaa ccacctcgtc ttaaacgcat tgagtcatgt tatcgatgtg

840

ttgacttatt tggccggtat ccacgagcaa tccactttcc aattttgtgc cattccccaa

900

gttatggcca ttgcaacctt ggctttggta ttcaacaacc gtgaagtgct acatggcaat

960

gtaaagattc gtaagggtac tacctgctat ttaattttga aatcaaggac tttgcgtggc

1020

tgtgtcgaga tttttgacta ttacttacgt gatatcaaat ctaaattggc tgtgcaagat

1080

ccaaatgcca gtaagacact aaaccgtctt gaagccgttc agaagtttat ggaagaaatg

1140

taccaggata aattacctcc taacgtgaag ccaaatgaaa ctccaatttt cttgaaagtt

1200

aaagaaagat ccagatacga tgatgaattg gttccaaccc aacaagaaga agagtacaag

1260

ttcaatatgg ttttatctat catcttgtcc gttcttcttg ggttttatta tatatacact

1320

ttacacagag cgtga

1335

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 144
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp357
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1033) .. (1071)

<400> SEQUENCE, 144
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900
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ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaaatctaa attggctgtg caagatccaa atttcttaaa aacactaaac

1080

cgacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 145
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp358
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1072) .. (1110)

<400> SEQUENCE, 145
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gttgaacatt

1080

caaatctcca agatcgaaca gtttatggaa gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 146
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp359
<220> FEATURE,
<221> NAME/KEY, misc_binding
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<222> LOCATION, (1090) .. (1101)
<400> SEQUENCE, 146
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atgccagtaa gacactaaac

1080

cgacttgaaa agatcgaaca gctctgcaga gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 147
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp360
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1063) .. (1083)

<400> SEQUENCE, 147
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600
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aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atttcttaaa attgaacatt

1080

caacttgaag ccgttcagaa actctgcaga gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 148
LENGTH, 1233
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, A. thaliana squalene synthase constructs cloned
into YEp361
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (1063) .. (1101)
<400> SEQUENCE, 148
atggggagct tggggacgat gctgagatat cccgatgata tatatccgct cctgaagatg

60

aaacgagcga ttgagaaagc ggagaagcag atccctcctg agccacactg gggtttctgc

120

tattcgatgc tccacaaggt ttctcgaagc ttttctctcg ttattcagca actcaacacc

180

gagctccgta acgccgtgtg tgtgttctac ttggttctcc gagctcttga tactgttgag

240

gatgatacta gcataccaac tgatgaaaag gttcccatcc tgatagcttt tcaccggcac

300

atatacgata ctgattggca ttattcatgt ggtacgaagg agtacaagat tctaatggac

360

caatttcacc atgtttctgc agcttttttg gaacttgaaa aagggtatca agaggctatc

420

gaggaaatta ctagaagaat gggtgcaggg atggccaagt ttatctgcca agaggtagaa

480

actgttgatg actacgatga atactgccac tatgttgctg ggcttgttgg tttaggtttg

540

tcgaaactct tcctcgctgc aggatcagag gttttgacac cagattggga ggcgatttcc

600

aattcaatgg gtttatttct acagaaaaca aacattatca gagattatct tgaggacatt

660

aatgagatac caaaatcccg catgttttgg cctcgcgaga tttggggcaa atatgctgac

720

aagcttgagg atttaaaata cgaggagaac acaaacaaat ccgtacagtg cttaaatgaa

780

atggttacca atgcgttgat gcatattgaa gattgcctga aatacatggt ttccttgcgt

840

gatccttcca tatttcggtt ctgtgccatc cctcagatca tggcgattgg aacacttgca

900

ttatgctata acaatgaaca agtattcaga ggcgttgtga aactgaggcg aggtcttact

960

gctaaagtca ttgatcgtac aaagacaatg gctgatgtct atggtgcttt ctatgatttt

1020

tcctgcatgc tgaagacaaa ggttgacaag aacgatccaa atttcttaaa attgaacatt

1080

caaatctcca agatcgaaca gctctgcaga gacgctggag ttcttcaaaa cagaaaatct

1140

tatgttaatg acaaaggaca accaaacagt gtctttatta taatggttgt gattctactg

1200

gccatagtct ttgcatatct cagagcaaac tga

1233
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<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 149
LENGTH, 282
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus S. cerevisiae squalene synthase
construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (282)
<400> SEQUENCE, 149

atgaaatcta aattggctgt gcaagatcca aatttcttaa aattgaacat tcaaatctcc

60

aagatcgaac agtttatgga agaaatgtac caggataaat tacctcctaa cgtgaagcca

120

aatgaaactc caattttctt gaaagttaaa gaaagatcca gatacgatga tgaattggtt

180

ccaacccaac aagaagaaga gtacaagttc aatatggttt tatctatcat cttgtccgtt

240

cttcttgggt tttattatat atacacttta cacagagcgt ga

282

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 150
LENGTH, 198
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus S. cerevisiae squalene synthase
construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (198)
<400> SEQUENCE, 150

atgtaccagg ataaattacc tcctaacgtg aagccaaatg aaactccaat tttcttgaaa

60

gttaaagaaa gatccagata cgatgatgaa ttggttccaa cccaacaaga agaagagtac

120

aagttcaata tggttttatc tatcatcttg tccgttcttc ttgggtttta ttatatatac

180

actttacaca gagcgtga

198

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 151
LENGTH, 204
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C-terminus A. thaliana squalene synthase
construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (204)
<400> SEQUENCE, 151
atgaagacaa aggttgacaa gaacgatcca aatgccagta agacactaaa ccgacttgaa

60

gccgttcaga aactctgcag agacgctgga gttcttcaaa acagaaaatc ttatgttaat

120

gacaaaggac aaccaaacag tgtctttatt ataatggttg tgattctact ggccatagtc

180

tttgcatatc tcagagcaaa ctga

204

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 152
LENGTH, 204
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus S. cerevisiae and A. thaliana
squalene synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (204)

117
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<400> SEQUENCE, 152
atgaaatcta aattggctgt gcaagatcca aatttcttaa aattgaacat tcaaatctcc

60

aagatcgaac agtttatgga agacgctgga gttcttcaaa acagaaaatc ttatgttaat

120

gacaaaggac aaccaaacag tgtctttatt ataatggttg tgattctact ggccatagtc

180

tttgcatatc tcagagcaaa ctga

204

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 153
LENGTH, 282
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus A. thaliana and S. cerevisiae
squalene synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (282)
<400> SEQUENCE, 153

atgaagacaa aggttgacaa gaacgatcca aatgccagta agacactaaa ccgacttgaa

60

gccgttcaga aactctgcag agaaatgtac caggataaat tacctcctaa cgtgaagcca

120

aatgaaactc caattttctt gaaagttaaa gaaagatcca gatacgatga tgaattggtt

180

ccaacccaac aagaagaaga gtacaagttc aatatggttt tatctatcat cttgtccgtt

240

cttcttgggt tttattatat atacacttta cacagagcgt ga

282

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 154
LENGTH, 291
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus B. braunii and S. cerevisiae
squalene synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (291)
<400> SEQUENCE, 154

atggaagtca gatgcaacac cgagaccagc gaggatccca gcgtgaccac cactctggaa

60

cacctgcata agatcaaagc tgcctgcaag gaaatgtacc aggataaatt acctcctaac

120

gtgaagccaa atgaaactcc aattttcttg aaagttaaag aaagatccag atacgatgat

180

gaattggttc caacccaaca agaagaagag tacaagttca atatggtttt atctatcatc

240

ttgtccgttc ttcttgggtt ttattatata tacactttac acagagcgtg a

291

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 155
LENGTH, 324
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: C-terminus S. cerevisiae and B. braunii
squalene synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (324)
<400> SEQUENCE, 155

atgaaatcta aattggctgt gcaagatcca aatttcttaa aattgaacat tcaaatctcc

60

aagatcgaac agtttatgga agccggcctg gcacgcacaa aagatgacac ctttgacgaa

120

ttgaggagca ggttgttagc gctgacggga ggcagcttct acctcgcctg gacctacaat

180
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ttcctagacc ttcgaggccc gggagacctg cccaccttct tatctgtaac ccaacattgg

240

tggtctattc tgatcttcct catttcgatt gccgtcttct ttattccgtc gaggccctca

300

cctagaccca cactcagcgc ctaa

324

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 156
LENGTH, 282
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fusion of Aspergillus squalene synthase - yeast
squalene synthase
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (4) .. (81)
<400> SEQUENCE, 156
atgcacaaga agaacacacc caaggacccc aatttcctaa aaatcagtat cgtctgcggc

60

aagattgaga aatttatcga ggaaatgtac caggataaat tacctcctaa cgtgaagcca

120

aatgaaactc caattttctt gaaagttaaa gaaagatcca gatacgatga tgaattggtt

180

ccaacccaac aagaagaaga gtacaagttc aatatggttt tatctatcat cttgtccgtt

240

cttcttgggt tttattatat atacacttta cacagagcgt ga

282

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 157
LENGTH, 2073
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Fluorescence protein tagged S. cerevisiae
squalene synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (715) .. (738)
<400> SEQUENCE, 157
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt

60

gatgttaatg gtcacaaatt ttctgtctcc ggtgaaggtg aaggtgatgc tacttacggt

120

aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta

180

gtcactactt tcggttatgg tgttcaatgt tttgcgagat acccagatca tatgaaacaa

240

catgactttt tcaagtctgc catgccagaa ggttatgttc aagaaagaac tatttttttc

300

aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaaggtga taccttagtt

360

aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa

420

ttggaataca actataactc tcacaatgtt tacatcatgg ctgacaaaca aaagaatggt

480

atcaaagtta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac

540

cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac

600

ttatccactc aatctgcctt atccaaagat ccaaacgaaa agacagacca catggtcttg

660

ttagaatttg ttactgctgc tggtattacc catggtatgg atgaattgta caaaggtggt

720

tctggtggtg gttctggtat gggaaagcta ttacaattgg cattgcatcc ggtcgagatg

780

aaggcagctt tgaagctgaa gttttgcaga acaccgctat tctccatcta tgatcagtcc

840

acgtctccat atctcttgca ctgtttcgaa ctgttgaact tgacctccag atcgtttgct

900

gctgtgatca gagagctgca tccagaattg agaaactgtg ttactctctt ttatttgatt

960

ttaagggctt tggataccat cgaagacgat atgtccatcg aacacgattt gaaaattgac

1020

ttgttgcgtc acttccacga gaaattgttg ttaactaaat ggagtttcga cggaaatgcc

1080
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cccgatgtga aggacagagc cgttttgaca gatttcgaat cgattcttat tgaattccac

1140

aaattgaaac cagaatatca agaagtcatc aaggagatca ccgagaaaat gggtaatggt

1200

atggccgact acatcttaga tgaaaattac aacttgaatg ggttgcaaac cgtccacgac

1260

tacgacgtgt actgtcacta cgtagctggt ttggtcggtg atggtttgac ccgtttgatt

1320

gtcattgcca agtttgccaa cgaatctttg tattctaatg agcaattgta tgaaagcatg

1380

ggtcttttcc tacaaaaaac caacatcatc agagattaca atgaagattt ggtcgatggt

1440

agatccttct ggcccaagga aatctggtca caatacgctc ctcagttgaa ggacttcatg

1500

aaacctgaaa acgaacaact ggggttggac tgtataaacc acctcgtctt aaacgcattg

1560

agtcatgtta tcgatgtgtt gacttatttg gccggtatcc acgagcaatc cactttccaa

1620

ttttgtgcca ttccccaagt tatggccatt gcaaccttgg ctttggtatt caacaaccgt

1680

gaagtgctac atggcaatgt aaagattcgt aagggtacta cctgctattt aattttgaaa

1740

tcaaggactt tgcgtggctg tgtcgagatt tttgactatt acttacgtga tatcaaatct

1800

aaattggctg tgcaagatcc aaatttctta aaattgaaca ttcaaatctc caagatcgaa

1860

cagtttatgg aagaaatgta ccaggataaa ttacctccta acgtgaagcc aaatgaaact

1920

ccaattttct tgaaagttaa agaaagatcc agatacgatg atgaattggt tccaacccaa

1980

caagaagaag agtacaagtt caatatggtt ttatctatca tcttgtccgt tcttcttggg

2040

ttttattata tatacacttt acacagagcg tga

2073

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 158
LENGTH, 2088
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Fluorescence protein tagged B. braunii squalene
synthase construct
<220> FEATURE,
<221> NAME/KEY, misc_binding
<222> LOCATION, (679) .. (702)
<400> SEQUENCE, 158
atggtgcgct cctccaagaa cgtcatcaag gagttcatgc gcttcaaggt gcgcatggag

60

ggcaccgtga acggccacga gttcgagatc gagggcgagg gcgagggccg cccctacgag

120

ggccacaaca ccgtgaagct gaaggtgacc aagggcggcc ccctgccctt cgcctgggac

180

atcctgtccc cccagttcca gtacggctcc aaggtgtacg tgaagcaccc cgccgacatc

240

cccgactaca agaagctgtc cttccccgag ggcttcaagt gggagcgcgt gatgaacttc

300

gaggacggcg gcgtggtgac cgtgacccaa gactcctccc tgcaggacgg ctgcttcatc

360

tacaaggtga agttcatcgg cgtgaacttc ccctccgacg gccccgtaat gcagaagaag

420

accatgggct gggaggcctc caccgagcgc ctgtaccccc gcgacggcgt gctgaagggc

480

gagatccaca aggccctgaa gctgaaggac ggcggccact acctggtgga gttcaagtcc

540

atctacatgg ccaagaagcc cgtgcagctg cccggctact actacgtgga ctccaagctg

600

gacatcacct cccacaacga ggactacacc atcgtggagc agtacgagcg caccgagggc

660

cgccaccacc tgttcctggg tggttctggt ggtggttctg gtatggggat gcttcgctgg

720

ggagtggagt ctttgcagaa tccagatgaa ttaatcccgg tcttgaggat gatttatgct

780

gataagtttg gaaagatcaa gccaaaggac gaagaccggg gcttctgcta tgaaatttta

840

aaccttgttt caagaagttt tgcaatcgtc atccaacagc tccctgcaca gctgagggac

900

US 9,821,037 Bl
123

124
-continued

ccagtctgca tattttacct tgtactacgc gccctggaca cagtcgaaga tgatatgaaa

960

attgcagcaa ccaccaagat tcccttgctg cgtgactttt atgagaaaat ttctgacagg

1020

tcattccgca tgacggccgg agatcaaaaa gactacatca ggctgttgga tcagtacccc

1080

aaagtgacaa gcgttttctt gaaattgacc ccccgtgaac aagagataat tgcagacatt

1140

acaaagcgga tggggaatgg aatggctgac ttcgtgcata agggtgttcc cgacacagtg

1200

ggggactacg acctttactg ccactatgtt gctggggtgg tgggtctcgg gctttcccag

1260

ttgttcgttg cgagtggact acagtcaccc tctttgaccc gcagtgaaga cctttccaat

1320

cacatgggcc tcttccttca gaagaccaac atcatccgcg actactttga ggacatcaat

1380

gagctgcctg ccccccggat gttctggccc agagagatct ggggcaagta tgcgaacaac

1440

ctcgctgagt tcaaagaccc ggccaacaag gcggctgcaa tgtgctgcct caacgagatg

1500

gtcacagatg cattgaggca cgcggtgtac tgcctgcagt acatgtccat gattgaggat

1560

ccgcagatct tcaacttctg tgccatccct cagaccatgg ccttcggcac cctgtctttg

1620

tgttacaaca actacactat cttcacaggg cccaaagcgg ctgtgaagct gcgtaggggc

1680

accactgcca agctgatgta cacctctaac aatatgtttg cgatgtaccg tcatttcctc

1740

aacttcgcag agaagctgga agtcagatgc aacaccgaga ccagcgagga tcccagcgtg

1800

accaccactc tggaacacct gcataagatc aaagctgcct gcaaggctgg gctggcacgc

1860

acaaaagatg acacctttga cgaattgagg agcaggttgt tagcgctgac gggaggcagc

1920

ttctacctcg cctggaccta caatttccta gaccttcgag gcccgggaga cctgcccacc

1980

ttcttatctg taacccaaca ttggtggtct attctgatct tcctcatttc gattgccgtc

2040

ttctttattc cgtcgaggcc ctcacctaga cccacactca gcgcctaa

2088

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<220>
<221>
<222>

SEQ ID NO 159
LENGTH, 2115
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
O THER INFORMATION, Fluorescence protein tagged B. braunii squalene
synthase construct
FEATURE,
NAME/KEY, misc_binding
LOCATION, (715) .. (738)
FEATURE,
NAME/KEY, misc_binding
LOCATION, (1795) .. (1872)

<400> SEQUENCE, 159
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt

60

gatgttaatg gtcacaaatt ttctgtctcc ggtgaaggtg aaggtgatgc tacttacggt

120

aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta

180

gtcactactt tcggttatgg tgttcaatgt tttgcgagat acccagatca tatgaaacaa

240

catgactttt tcaagtctgc catgccagaa ggttatgttc aagaaagaac tatttttttc

300

aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaaggtga taccttagtt

360

aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa

420

ttggaataca actataactc tcacaatgtt tacatcatgg ctgacaaaca aaagaatggt

480

atcaaagtta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac

540

cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac

600

ttatccactc aatctgcctt atccaaagat ccaaacgaaa agacagacca catggtcttg

660
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ttagaatttg ttactgctgc tggtattacc catggtatgg atgaattgta caaaggtggt

720

tctggtggtg gttctggtat ggggatgctt cgctggggag tggagtcttt gcagaatcca

780

gatgaattaa tcccggtctt gaggatgatt tatgctgata agtttggaaa gatcaagcca

840

aaggacgaag accggggctt ctgctatgaa attttaaacc ttgtttcaag aagttttgca

900

atcgtcatcc aacagctccc tgcacagctg agggacccag tctgcatatt ttaccttgta

960

ctacgcgccc tggacacagt cgaagatgat atgaaaattg cagcaaccac caagattccc

1020

ttgctgcgtg acttttatga gaaaatttct gacaggtcat tccgcatgac ggccggagat

1080

caaaaagact acatcaggct gttggatcag taccccaaag tgacaagcgt tttcttgaaa

1140

ttgacccccc gtgaacaaga gataattgca gacattacaa agcggatggg gaatggaatg

1200

gctgacttcg tgcataaggg tgttcccgac acagtggggg actacgacct ttactgccac

1260

tatgttgctg gggtggtggg tctcgggctt tcccagttgt tcgttgcgag tggactacag

1320

tcaccctctt tgacccgcag tgaagacctt tccaatcaca tgggcctctt ccttcagaag

1380

accaacatca tccgcgacta ctttgaggac atcaatgagc tgcctgcccc ccggatgttc

1440

tggcccagag agatctgggg caagtatgcg aacaacctcg ctgagttcaa agacccggcc

1500

aacaaggcgg ctgcaatgtg ctgcctcaac gagatggtca cagatgcatt gaggcacgcg

1560

gtgtactgcc tgcagtacat gtccatgatt gaggatccgc agatcttcaa cttctgtgcc

1620

atccctcaga ccatggcctt cggcaccctg tctttgtgtt acaacaacta cactatcttc

1680

acagggccca aagcggctgt gaagctgcgt aggggcacca ctgccaagct gatgtacacc

1740

tctaacaata tgtttgcgat gtaccgtcat ttcctcaact tcgcagagaa gcttaaatct

1800

aaattggctg tgcaagatcc aaatttctta aaattgaaca ttcaaatctc caagatcgaa

1860

cagtttatgg aagccggcct ggcacgcaca aaagatgaca cctttgacga attgaggagc

1920

aggttgttag cgctgacggg aggcagcttc tacctcgcct ggacctacaa tttcctagac

1980

cttcgaggcc cgggagacct gcccaccttc ttatctgtaa cccaacattg gtggtctatt

2040

ctgatcttcc tcatttcgat tgccgtcttc tttattccgt cgaggccctc acctagaccc

2100

acactcagcg cctaa

2115

<210>
<211>
<212>
<213>

SEQ ID NO 160
LENGTH, 26
TYPE, PRT
ORGANISM: Trypanosoma cruzi

<400> SEQUENCE, 160
Ala Ala Arg Met Asn Ala Gln Asp Ala Cys Tyr Asp Arg Ile Glu His
1
5
10
15
Leu Val Asn Asp Ala Ile Arg Ala Met Glu
20
25
<210>
<211>
<212>
<213>

SEQ ID NO 161
LENGTH, 26
TYPE, PRT
ORGANISM: Leishmania donovani

<400> SEQUENCE, 161
Gln Lys Lys Leu Asp Val Gln Asp Ala Ser Ser Thr Ser Ile Ala Asn
1
5
10
15
Ser Leu Ala Ala Ala Ile Glu Arg Ile Asp
20
25
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The invention claimed is:
1. A compound consisting of an amino acid sequence
selected from the group consisting of SEQ ID NOs: 1-12 and
161, wherein the compound inhibits fungal growth.
2. The compound of claim 1, wherein the amino acid 5
sequence is SEQ ID NO: 1.
3. The compound of claim 1, wherein the amino acid
sequence is selected from the group consisting of SEQ ID
NOs: 2-12.

* * * * *
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